From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Mon, 26 Dec 2022 19:26:23 +0000
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Walke, Henry (CDC/DDPHSIS/CPR/OD)
Subject: Re: IM slides_predeparture testing_final.pptx

Don't know yet. Will find out after Deputies.

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Monday, December 26, 2022 1:24:38 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Agree. We need to (b)(5)

(b)(5)

Nicky.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 2:20 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: Re: IM slides_predeparture testing_final.pptx

I've heard different things about this but sounded like from an article I read, when the previous policy was in place in China for testing every 48h, they had a large network of pcr testing locations. Then they started closing those and reverting to people doing at home ag tests with self reporting once they stopped most zero Covid measures. (b)(5)

(b)(5)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Monday, December 26, 2022 1:13:25 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 2:11 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ)
Sent: Monday, December 26, 2022 2:06 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Monday, December 26, 2022 2:03 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Nicky.

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 1:56 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Monday, December 26, 2022 1:43 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Thanks, Nicky!

Henry, are you tracking what needs to go to into the paper?

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Monday, December 26, 2022 1:41 PM

To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Nicky.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 1:23 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Subject: Re: IM slides_predeparture testing_final.pptx

Adding Nicky

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:17:09 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: IM slides_predeparture testing_final.pptx

(b)(5)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:07:08 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa

(CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

Fig. 3


A
Reduction in transmission risk (%)
0
20
40
60
80
100
Symp. monitoring
Test alone
Test + symp. monitoring
No test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)
B
Reduction in transmission risk (%)
0
20
40
60
80
100
95% sensitivity antigen test
80% sensitivity antigen test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)

Reductions in SARS-CoV-2 transmission during travel. **a** Reduction in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel, stratified by method of risk reduction. Individuals developing symptoms are assumed to be isolated and therefore do not travel. **b** Reductions in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel comparing the antigen assays with 80% and 95% sensitivity. Ranges indicate uncertainty from the different infectiousness models

---

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 1:01 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

This page has what you want



Fig. 2 Reductions in total average SARS-CoV-2 transmission risk after infection at a known high-risk exposure time (day 0) without considering travel. Transmission risk reductions are stratified by method of risk reduction including symptom monitoring, quarantine (7 or 14 days), and testing (test on days 1–7). Symptom monitoring is assumed to be ongoing regardless of the test date when implemented and either symptom onset or a positive test result is assumed to result in immediate isolation until the individual is no longer infectious. The bars represent the median estimates and the error bars show the ranges (minima and maxima) across the different infectiousness curves and test positivity curves (when testing was included)

effective at detecting infections; later testing means that while the test was more likely to be positive, the infectious period may begin prior to the test, leading to a smaller reduction in risk.

Combining symptom monitoring or quarantine with testing provided added benefit, leading to increased risk reduction, especially with a test at day 3–5 post-exposure with symptom monitoring (47–75% reduction with 30% never symptomatic or 39–73% with 50% never symptomatic) or a test at day 5–7 with a 7-day quarantine (76–95% reduction). A 7-day quarantine with symptom monitoring and a test at day 5–7 further increased the lower bound of likely risk reduction to 91–98% (with 30% never symptomatic, 86–97% with 50% never symptomatic). The effect of moderately different assumptions related to the proportion of infections that never result in symptoms had minimal impacts when symptom monitoring was combined with testing or quarantine, we therefore use the 30% value for this parameter in the following analyses.

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

We assessed the impact of test sensitivity relative to timing by comparing the antigen-type test model to the same model with higher sensitivity. With the same time-specific pattern but different sensitivity (80% vs. 95%, Fig. 3b), the higher sensitivity test gives a higher reduction in transmission risk if used at the same time. However, the importance of sensitivity is intertwined with timing. The lower sensitivity test was as effective or more effective than a higher sensitivity test if it was performed closer to the time of travel. For example, the test with 80% sensitivity performed 1 day prior to departure was 47–58% effective at reducing transmission risk during travel, while the test with 95% sensitivity performed 3 days prior to departure was 18–35% effective.

Transmission risk after travel

We then considered measures to reduce the risk of SARS-CoV-2 introduction to the destination location from travelers, i.e., transmission risk after traveling (Fig. 4). Assuming infection occurs at an unknown time within a 7-day exposure period prior to arrival (i.e., including possible infection while traveling), a single test on its own was most effective when performed 1- or 2-days post-arrival (29–53% and 29–51% reduction in transmission risk, respectively). This reduction in introduction risk was higher than reductions generated by

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention

Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:49 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Thank you, (b)(5)

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 12:46 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:42 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Julia,

(b)(6). Can you work with Cindy to get the BLUF answer for Nancy K. question to add to the Sherri doc? (b)(5)

(b)(5)

(b)(5)

L

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Monday, December 26, 2022 12:30 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: FW: IM slides_predeparture testing_final.pptx

Resending this to the top of your email box Henry. (b)(5)

(b)(5)

(b)(5) Cindy can confirm.

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 22, 2022 10:48 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: IM slides_predeparture testing_final.pptx

Henry,

Here are the slides from IM and an abstract for an upcoming mtg that is 90% cleared.

I would just highlight that we should be (b)(5)

(b)(5)

Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Mon, 26 Dec 2022 18:07:08 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: IM slides_predeparture testing_final.pptx
Attachments: Johannssen model paper.pdf

(b)(5)

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

Fig. 3


A
Reduction in transmission risk (%)
0
20
40
60
80
100
Symp. monitoring
Test alone
Test + symp. monitoring
No test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)
B
Reduction in transmission risk (%)
0
20
40
60
80
100
95% sensitivity antigen test
80% sensitivity antigen test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)

Reductions in SARS-CoV-2 transmission during travel. **a** Reduction in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel, stratified by method of risk reduction. Individuals developing symptoms are assumed to be isolated and therefore do not travel. **b** Reductions in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel comparing the antigen assays with 80% and 95% sensitivity. Ranges indicate uncertainty from the different infectiousness models

---

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 1:01 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

This page has what you want



Fig. 2 Reductions in total average SARS-CoV-2 transmission risk after infection at a known high-risk exposure time (day 0) without considering travel. Transmission risk reductions are stratified by method of risk reduction including symptom monitoring, quarantine (7 or 14 days), and testing (test on days 1–7). Symptom monitoring is assumed to be ongoing regardless of the test date when implemented and either symptom onset or a positive test result is assumed to result in immediate isolation until the individual is no longer infectious. The bars represent the median estimates and the error bars show the ranges (minima and maxima) across the different infectiousness curves and test positivity curves (when testing was included)

effective at detecting infections; later testing means that while the test was more likely to be positive, the infectious period may begin prior to the test, leading to a smaller reduction in risk.

Combining symptom monitoring or quarantine with testing provided added benefit, leading to increased risk reduction, especially with a test at day 3–5 post-exposure with symptom monitoring (47–75% reduction with 30% never symptomatic or 39–73% with 50% never symptomatic) or a test at day 5–7 with a 7-day quarantine (76–95% reduction). A 7-day quarantine with symptom monitoring and a test at day 5–7 further increased the lower bound of likely risk reduction to 91–98% (with 30% never symptomatic, 86–97% with 50% never symptomatic). The effect of moderately different assumptions related to the proportion of infections that never result in symptoms had minimal impacts when symptom monitoring was combined with testing or quarantine, we therefore use the 30% value for this parameter in the following analyses.

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

We assessed the impact of test sensitivity relative to timing by comparing the antigen-type test model to the same model with higher sensitivity. With the same time-specific pattern but different sensitivity (80% vs. 95%, Fig. 3b), the higher sensitivity test gives a higher reduction in transmission risk if used at the same time. However, the importance of sensitivity is intertwined with timing. The lower sensitivity test was as effective or more effective than a higher sensitivity test if it was performed closer to the time of travel. For example, the test with 80% sensitivity performed 1 day prior to departure was 47–58% effective at reducing transmission risk during travel, while the test with 95% sensitivity performed 3 days prior to departure was 18–35% effective.

Transmission risk after travel

We then considered measures to reduce the risk of SARS-CoV-2 introduction to the destination location from travelers, i.e., transmission risk after traveling (Fig. 4). Assuming infection occurs at an unknown time within a 7-day exposure period prior to arrival (i.e., including possible infection while traveling), a single test on its own was most effective when performed 1- or 2-days post-arrival (29–53% and 29–51% reduction in transmission risk, respectively). This reduction in introduction risk was higher than reductions generated by

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention

Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:49 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Thank you, (b)(5)

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 12:46 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:42 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Julia,

(b)(6) Can you work with Cindy to get the BLUF answer for Nancy K. question to add to the Sherri doc? (b)(5)

(b)(5)

(b)(5)

L

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Monday, December 26, 2022 12:30 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: FW: IM slides_predeparture testing_final.pptx

Resending this to the top of your email box Henry. (b)(5)
(b)(5)
(b)(5) Cindy can confirm.

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 22, 2022 10:48 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: IM slides_predeparture testing_final.pptx

Henry,

Here are the slides from IM and an abstract for an upcoming mtg that is 90% cleared.

I would just highlight that we should be (b)(5)

(b)(5)

Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

Johansson et al. BMC Medicine (2021) 19:94
https://doi.org/10.1186/s12916-021-01975-w

BMC Medicine

RESEARCH ARTICLE Open Access

Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing

Michael A. Johansson*, Hannah Wolford, Prabasaj Paul, Pamela S. Diaz, Tai-Ho Chen, Clive M. Brown, Martin S. Cetron and Francisco Alvarado-Ramy

Abstract

Background: Balancing the control of SARS-CoV-2 transmission with the resumption of travel is a global priority. Current recommendations include mitigation measures before, during, and after travel. Pre- and post-travel strategies including symptom monitoring, antigen or nucleic acid amplification testing, and quarantine can be combined in multiple ways considering different trade-offs in feasibility, adherence, effectiveness, cost, and adverse consequences.

Methods: We used a mathematical model to analyze the expected effectiveness of symptom monitoring, testing, and quarantine under different estimates of the infectious period, test-positivity relative to time of infection, and test sensitivity to reduce the risk of transmission from infected travelers during and after travel.

Results: If infection occurs 0–7 days prior to travel, immediate isolation following symptom onset prior to or during travel reduces risk of transmission while traveling by 30–35%. Pre-departure testing can further reduce risk, with testing closer to the time of travel being optimal even if test sensitivity is lower than an earlier test. For example, testing on the day of departure can reduce risk while traveling by 44–72%. For transmission risk after travel with infection time up to 7 days prior to arrival at the destination, isolation based on symptom monitoring reduced introduction risk at the destination by 42–56%. A 14-day quarantine after arrival, without symptom monitoring or testing, can reduce post-travel risk by 96–100% on its own. However, a shorter quarantine of 7 days combined with symptom monitoring and a test on day 5–6 after arrival is also effective (97–100%) at reducing introduction risk and is less burdensome, which may improve adherence.

(Continued on next page)

* Correspondence: mjohansson@cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, USA

(Continued from previous page)
Conclusions: Quarantine is an effective measure to reduce SARS-CoV-2 transmission risk from travelers and can be enhanced by the addition of symptom monitoring and testing. Optimal test timing depends on the effectiveness of quarantine: with low adherence or no quarantine, optimal test timing is close to the time of arrival; with effective quarantine, testing a few days later optimizes sensitivity to detect those infected immediately before or while traveling. These measures can complement recommendations such as social distancing, using masks, and hand hygiene, to further reduce risk during and after travel.

Keywords: SARS-CoV-2, COVID-19, Travel, Testing, Quarantine

Background

Coronavirus disease 2019 (COVID-19) was first recognized in late December 2019. By March 2020, the virus causing COVID-19, SARS-CoV-2, had reached 6 continents and almost 70 countries. In response to the global COVID-19 outbreak, governments implemented a variety of mitigation measures including unprecedented social distancing measures, travel health alerts, and travel restrictions at national and sub-national levels [1, 2]. These measures, as well as concern about exposures related to travel, led to major and prolonged reductions in air travel worldwide [3–7]. Spatiotemporally asynchronous waves of COVID-19 have led to dynamic risk and mitigation measures globally with an accompanying interest in identifying risk management steps for travel that can reduce the risk of transmission and address concerns of travelers, travel industry regulators, and public health authorities [8–10].

Initial policies for managing translocation of the virus from one destination to another relied on closing borders or restricting entry of travelers from countries with higher incidence rates [11, 12]. Although these approaches may have reduced the importation of some cases and preserved resources, they came with enormous economic and individual impacts [13, 14].

For travelers, personal mitigation actions include wearing masks, social distancing at least 6 ft from others when possible, frequent hand washing or use of alcohol-based hand sanitizer, not touching their face, and avoiding anyone who is sick. Governments, airlines, airports, and other businesses serving travelers have implemented or recommended measures to reduce the risk of COVID-19 associated with air travel [15, 16]. These measures have included enhanced disinfection procedures, employee health assessments, passenger health attestations, screening for fever, illness response protocols, increased spacing between passengers on flights, and other steps to reduce risk of transmission in airports and on conveyances [10, 17]. Symptom-based screening at airports has proven ineffective because those measures miss mild, afebrile, asymptomatic, and pre-symptomatic SARS-CoV-2 infections [18–21]. Asymptomatic persons may account for 20% to 40% of SARS-CoV-2 infections and can transmit the virus to others [22–27], and epidemiological data indicate that infectiousness begins prior to symptom onset for those who do develop symptoms [28–32].

In many destinations, arriving travelers, most of whom are asymptomatic with no specific known exposures, were asked to self-quarantine and reduce contacts as much as possible after arrival. The World Health Organization (WHO) defines quarantine as "the restriction of activities and/or separation from others of the suspect persons... who are not ill, in such a manner as to prevent the possible spread of infection" and indicates that quarantine may be considered for travelers based on risk assessment and local conditions. For known SARS-CoV-2 exposures, WHO recommends quarantine of 14 days from their last exposure based on the limit of the estimated incubation period for SARS-CoV-2 [33]. A 14-day quarantine alone, when implemented immediately post-exposure and strictly adhered to, approaches 100% reduction in post-exposure transmission risk [34, 35]. However, travelers may have little incentive to consistently adhere to these measures at their destinations unless there is the ability to reliably communicate with them, support their needs, and enforce these measures. Monitoring and enforcing adherence to quarantine measures requires tremendous effort and resources by public health entities that may only be feasible and appropriate in certain contexts [36, 37].

Inclusion of SARS-CoV-2 testing as a component of a multi-layered approach to risk-reduction is currently being implemented in various settings. Some businesses and educational institutions are incorporating SARS-CoV-2 screening strategies into their concepts of operations, sometimes including mandatory testing of employees and voluntary testing for customers [38–40]. While there is no current international standard for testing travelers, many countries and jurisdictions are requiring arriving travelers to be tested either prior to their departure or after arrival to identify infected persons who are asymptomatic so they can be isolated [41]. Current guidance or requirements vary from country to country, and from state to state within the USA, including the timing of the

test prior to or after travel, the type of test used (viral antigen, viral RNA), and the use of negative test results to alleviate additional public health measures, such as quarantine, at the destination [42, 43].

Currently available SARS-CoV-2 tests for detecting active infections include nucleic acid amplification tests (NAAT), such as reverse transcription polymerase chain reaction (RT-PCR) tests, rapid isothermal NAATs, and antigen-based tests. Time to deliver results is hours to days for RT-PCR and minutes to hours for antigen tests, which can also be processed without a specialized laboratory. Several antigen tests for SARS-CoV-2 are currently authorized in the United States for suspected SARS-CoV-2 infection [44, 45]. While rapid antigen tests have advantages over NAATs in terms of cost, simplicity, and turnaround time, they are less likely to detect a positive in individuals with low viral load, i.e., early or late in infection [46]. However, the limited available data on the efficacy of antigen testing in asymptomatic individuals suggests they may have high sensitivity for infectious individuals [46–49].

SARS-CoV-2 transmission risk related to travel can be viewed in two domains: transmission risk during travel (e.g., by infected travelers while at an airport or on aircraft) and after travel is completed (e.g., introduction or re-introduction of SARS-CoV-2 to the destination location). There is also overlap as transmission risk during travel can lead to new infections, which can increase post-travel risk. Data on strategies for reducing risk associated with travel are scant and there are many potential strategies (e.g., the optimal timing of pre-departure or post-arrival testing or the combination of testing and post-arrival quarantine) [39, 50–52]. Mathematical models have provided some insights to the potential impact of quarantine combined with testing [51, 53]. Here, we build upon those models, considering uncertainty in infectious periods and different testing options to assess a suite of possible combined pre- and post-travel strategies to reduce transmission risk from infected travelers.

Methods

First, we characterized component processes related to transmission risk during infection: the relative infectiousness over the course of infection, the proportion of infections resulting in symptoms, the timing of symptom onset for those who have symptoms, and the probability of testing positive over the course of infection.

We used three distinct models to characterize relative infectiousness over time, $I(t)$, specifying each as a density function of daily infectiousness such that the total infectiousness is equal to one and the curves only differ in the temporal distribution of transmission risk (Fig. 1a). We used a Gamma density function to approximate a 10-day infectious period with peak infectiousness on day 5 based on observations from numerous studies [27, 54–58]. We also replicated a within-host infection model by Goyal et al. [59] by simulating infections in 10,000 individuals and recording the probability of being infectious at time steps of 0.1 days. We then fitted a density function to the set of times when these individuals were infectious. This indicated that most people are infectious from days 3 to 7 after the time they were infected, with tapering afterwards. The final model characterizes simulated infectious periods from Clifford et al. [51], based on estimated latent periods (the delay between infection and becoming infectious) [54] and infectious periods [60]. We simulated 10,000 individual-level paired latent and infectious periods then fit an empirical density function to the infectious time points. The Gamma model represents a simple assumption that does not capture individual level variability; however, both the Goyal et al. and Clifford et al. infectiousness models capture the population-level impacts of individual-level variability such that estimates based on these models may more completely reflect the potential impact across many individuals.

We assumed that 70% of all infections result in symptomatic COVID-19 cases [25], σ_0, and provided several additional sensitivity estimates assuming that 50% of infections result in symptoms. For the incubation period, $\sigma(t)$, we used a meta-estimate with a median of 5 days and a Log-Normal distribution based on a meta-analysis by McAloon et al. [61].

For diagnostic testing, $\rho(t)$, we used two models: one directly estimating positivity by RT-PCR and one approximating an antigen detection assay (Fig. 1b). For the RT-PCR model, we used the model generated by Clifford et al. [51] based on data from Kucirka et al. [62]. To approximate an antigen detection assay, we assumed that the assay would have 80% sensitivity, s, for infectious individuals [46–49] and scaled the probability of testing, ρ, to match the time-course of each infectiousness curve with a peak at 80%:

$$\rho(t) = sI(t)/\max(I). \quad (1)$$

To assess the impact of test sensitivity we also compared this to a 95% sensitivity version of the same model.

We then constructed a model capturing these components to assess the impacts of testing, symptom monitoring, and quarantine (Table 1). Infections resulting in travel-related risk could occur before or during a trip and we use one of the infectiousness density functions described above, $I(t)$, which defines relative infectiousness at time t relative to travel based on infection at time τ relative to travel (prior to travel is negative):



Fig. 1 Models of relative infectiousness and the probability of testing positive relative to time since SARS-CoV-2 infection. **a** Infectiousness density functions for a Gamma density function approximating a 10-day infectious period with a peak on day 5 [54–58], a host infection model adopted from Goyal et al. [59], and simulated infectious and latent periods adopted from Clifford et al. [51]. **b** Models of the probability of a positive test for SARS-CoV-2 relative to time since infection: a distribution estimating positivity by RT-PCR adopted from Clifford et al. [51] and antigen ("Ag") testing curves for each infectiousness curve (**a**) scaled such that test positivity tracks infectiousness with a maximum sensitivity of 80% at peak infectiousness

$$I(t,\tau) = I(t-\tau). \quad (2)$$

Symptom monitoring was assessed as a method to detect and isolate infected individuals and therefore prevent transmission after symptom onset. As described above, we assumed that a proportion of infected individuals develop symptoms (σ_0) and develop symptoms at rate $\sigma(t)$ as defined by the incubation period (described above). The onset of symptoms was assumed to lead to isolation until recovery, resulting in a residual in transmission risk over the transmission window:

$$r_S(t,\tau) = 1-\sigma_0\sigma(t-\tau). \quad (3)$$

Transmission at a time t can also be mitigated through quarantine. We estimated the impact of quarantine as a reduction in risk of a magnitude equal to the adherence $\propto_Q$ $(1 = 100\%)$ during a quarantine of duration T_Q starting at the time of arrival t_0 with residual transmission risk:

$$r_Q(t) = 1-\propto_Q \text{if } t\in[t_0, t_0 + T_Q], \text{and 1 otherwise.} \quad (4)$$

Transmission can also be mitigated through test-based detection followed by isolation. For the purposes of the model, we assumed that test results were immediately available and a positive test immediately led to isolation until recovery. Test positivity for each test (described above) was characterized $\rho(t)$ and the corresponding residual in transmission associated with each test k at test time t_k is:

$$r_T(t,\tau,t_k) = 1-\rho(t_k-\tau) \text{ if } t\in[t_k,\infty], \text{and 1 otherwise.} \quad (5)$$

For a set of tests, K, the residual risk is the product:

Table 1 Model parameters

Variable	Definition	Values used
t	Time of transmission risk from traveler relative to time of travel	Ranges: 0–1 days while traveling, 0–28 days after travel
τ	Time of infection risk to traveler relative to time of travel	0 or ranges: 1–7 days pre-departure, 1–7 days pre-arrival
$I(t, \tau)$	Infectiousness	Functions shown in Fig. 1a [27, 51, 59]
σ_0	Proportion of infected individuals that develop symptoms	70%, 50%
$\sigma(t, \tau)$	Cumulative probability of developing symptoms among individuals who develop symptoms	Log-Normal cumulative distribution function [61]
t_0	Time of quarantine relative to the time of travel	0
$\propto_Q$	Adherence to quarantine	100%, 50%
T_Q	Duration of quarantine starting at t_0	7, 10, 14 days
t_k	Time of test k	6 days pre-departure to 7 days post-arrival
$\rho(t_k, \tau)$	Probability of a positive test	Functions shown in Fig. 1b
$\epsilon(\tau)$	Risk of infection	Uniform distribution

$$r_T^K(t,\tau) = \prod_{k=1}^{K} r_T(t,\tau,t_k) \quad (6)$$

Here, we assessed two transmission windows: days 0–1 for risk during travel to include potential risk in transit prior to and after airline travel and days 0–28 for risk after travel. The total transmission risk between times t_1 and t_2 for individuals infected at time τ is:

$$I_0(\tau) = \int_{t_1}^{t_2} I(t,\tau)dt. \quad (7)$$

The transmission risk prevented by protocols including symptom monitoring, quarantine, and testing is:

$$I_{SQT}^K(\tau) = \int_{t_1}^{t_2} I(t,\tau)\left(1-r_S(t,\tau)r_Q(t)r_T^K(t,\tau)\right)dt. \quad (8)$$

For exposure windows in which a unique time of exposure is unknown, we assumed that infection may have occurred at any time in that window with equal probability. We therefore define the risk of exposure $\epsilon(\tau)$ as uniformly distributed over a window defined by the beginning and end of the exposure period, τ_1 and τ_2, respectively:

$$\epsilon(\tau) = 1/(\tau_2-\tau_1) \text{ if } \tau\in[\tau_1-\tau_2], \text{and 0 otherwise.} \quad (9)$$

For example, with a 1-day trip, infection between 7 days pre-departure and the time of departure can be modeled relative to the time of arrival with $\tau_1 = -8$ and $\tau_2 = -1$.

Total infectiousness is then:

$$I_0 = \int_{\tau_1}^{\tau_2}\int_{t_1}^{t_2} I(t,\tau)dtd\tau. \quad (10)$$

The prevented transmission risk is:

$$I_{SQT}^K = \int_{\tau_1}^{\tau_2}\int_{t_1}^{t_2} \epsilon(\tau)I(t,\tau) \times \left(1-r_S(t,\tau)r_Q(t)r_T^K(t,\tau)\right)dtd\tau. \quad (11)$$

Finally, we calculate the proportional reduction in transmission risk as: I_{SQT}^K/I_0.

All analyses were conducted in R and the code is available at https://github.com/cdcepi/COVID-19-traveler-model.

Results

Reducing transmission risk after a specific known exposure

Before looking at exposure over a range of times, we first assessed the impact of symptom monitoring, quarantine, and testing when the time of infection was known (for example, a brief high-risk contact). Isolating infected individuals at the time of symptom onset, without testing or quarantine, resulted in a reduction in transmission risk of 36–52% (minimum to maximum) accounting for differences in infectiousness over time between models relative to the onset of symptoms and an assumption that 30% of infected individuals never develop symptoms. If the proportion of individuals who never have symptoms was higher, the effect of symptom monitoring decreased. For example, if 50% of individuals never had symptoms, the reduction from symptom monitoring decreased to 26–37%. Quarantine alone implemented immediately following exposure led to higher reductions in transmission risk, from 39 to 75% with 7 days to 90–100% with 14 days. Isolating individuals based on a single positive test result alone produced a 0–67% reduction in transmission, depending on the day of the test relative to the infectious period and the time-specific test sensitivity (Fig. 2). Testing earlier in infection was less



Fig. 2 Reductions in total average SARS-CoV-2 transmission risk after infection at a known high-risk exposure time (day 0) without considering travel. Transmission risk reductions are stratified by method of risk reduction including symptom monitoring, quarantine (7 or 14 days), and testing (test on days 1–7). Symptom monitoring is assumed to be ongoing regardless of the test date when implemented and either symptom onset or a positive test result is assumed to result in immediate isolation until the individual is no longer infectious. The bars represent the median estimates and the error bars show the ranges (minima and maxima) across the different infectiousness curves and test positivity curves (when testing was included)

effective at detecting infections; later testing means that while the test was more likely to be positive, the infectious period may begin prior to the test, leading to a smaller reduction in risk.

Combining symptom monitoring or quarantine with testing provided added benefit, leading to increased risk reduction, especially with a test at day 3–5 post-exposure with symptom monitoring (47–75% reduction with 30% never symptomatic or 39–73% with 50% never symptomatic) or a test at day 5–7 with a 7-day quarantine (76–95% reduction). A 7-day quarantine with symptom monitoring and a test at day 5–7 further increased the lower bound of likely risk reduction to 91–98% (with 30% never symptomatic, 86–97% with 50% never symptomatic). The effect of moderately different assumptions related to the proportion of infections that never result in symptoms had minimal impacts when symptom monitoring was combined with testing or quarantine, we therefore use the 30% value for this parameter in the following analyses.

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

We assessed the impact of test sensitivity relative to timing by comparing the antigen-type test model to the same model with higher sensitivity. With the same time-specific pattern but different sensitivity (80% vs. 95%, Fig. 3b), the higher sensitivity test gives a higher reduction in transmission risk if used at the same time. However, the importance of sensitivity is intertwined with timing. The lower sensitivity test was as effective or more effective than a higher sensitivity test if it was performed closer to the time of travel. For example, the test with 80% sensitivity performed 1 day prior to departure was 47–58% effective at reducing transmission risk during travel, while the test with 95% sensitivity performed 3 days prior to departure was 18–35% effective.

Transmission risk after travel

We then considered measures to reduce the risk of SARS-CoV-2 introduction to the destination location from travelers, i.e., transmission risk after traveling (Fig. 4). Assuming infection occurs at an unknown time within a 7-day exposure period prior to arrival (i.e., including possible infection while traveling), a single test on its own was most effective when performed 1- or 2-days post-arrival (29–53% and 29–51% reduction in transmission risk, respectively). This reduction in introduction risk was higher than reductions generated by



Fig. 3 Reductions in SARS-CoV-2 transmission during travel. **a** Reduction in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel, stratified by method of risk reduction. Individuals developing symptoms are assumed to be isolated and therefore do not travel. **b** Reductions in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel comparing the antigen assays with 80% and 95% sensitivity. Ranges indicate uncertainty from the different infectiousness models

testing prior to travel; a test 1 day prior to arrival provided a 17–35% reduction in risk and a test 3 days prior to arrival provided an 5–13% reduction (not shown). Tests prior to travel do not detect travelers infected while traveling and were less likely to detect travelers infected close to the time of travel. These travelers are those who are most likely to experience their entire infectious period in the destination location, and therefore, pose the greatest introduction risk.

Although a pre-travel test was less effective on its own than a post-travel test, the combination of pre-travel and post-travel tests provided additional risk reduction. A pre-travel test was most effective at reducing transmission risk after travel when performed close to the time of travel (as described above for risk during travel). In the absence of post-arrival quarantine, a second test post-travel was optimal 2–3 after arrival. The pre-travel test was likely to detect individuals who were infectious upon arrival and the later test was likely to detect those who became infectious after arrival. Combined, these tests can reduce introduction risk by 37–75%. A similar effect can be attained by testing immediately upon arrival and again 2–4 days post-arrival, which reduced introduction risk by 47–82%.

Symptom monitoring and isolation before, during, and after travel, with no other measures in place, reduced introduction risk by 42–56% and was more effective when combined with testing (Fig. 4). For example, a test 1-day post-arrival combined with symptom monitoring before, during, and after travel reduced introduction risk by 57–75%. However, quarantine for 7 days or more on its own was more effective than testing combined with symptom monitoring, regardless of when the test occurred. A 14-day quarantine reduced transmission risk by 96–100%, a 10-day quarantine by 84–100%, and a 7-day quarantine by 64–95% (Fig. 5). Testing and symptom monitoring further enhanced the effectiveness of quarantine. A single test conducted 5–6 days after arrival with symptom monitoring and a 7-day quarantine reduced introduction risk by 97--100% (Fig. 4). The day



Fig. 4 Reductions in SARS-CoV-2 transmission risk from infected travelers post-arrival. Reduction in transmission risk after arrival assuming a 7-day exposure window prior to arrival, stratified by day of test and symptom monitoring, with and without a 7-day quarantine. Symptom monitoring is assumed to be ongoing before, during, and after travel and either symptom onset or a positive test result is assumed to result in immediate isolation until the individual is no longer infectious

5–6 window is optimal because it balances the reduced risk while in quarantine, with higher sensitivity for detecting individuals who may remain infectious at the end of the quarantine period.

A 7-day quarantine in conjunction with symptom monitoring and testing had similar effectiveness to a 10-day or 14-day quarantine on its own. Comparing quarantine with imperfect adherence (50%), we found that with symptom monitoring and no test, a 7-day quarantine (70–72%) was likely to be almost as effective as a 14-day quarantine (71–77%; Fig. 5). Combined with a test within 0–3 days after arrival and symptom monitoring, a 7-day quarantine with 50% adherence was estimated to be more effective (77–86%) than a 14-day quarantine with 50% adherence and no test (71–77%) and as effective as a 14-day quarantine with a test (77–88%).

Discussion

Control of SARS-CoV-2 is contingent upon multiple layered mitigation measures. Reducing the risk of



Fig. 5 Reductions in transmission risk post-arrival assuming a 7-day exposure window prior to arrival and symptom monitoring, stratified by quarantine length, quarantine adherence, and day of test

transmission associated with travel is critical to reducing the impact related to importations on local health and healthcare systems. This is important when transmission at the destination is low and an introduction could spur additional outbreaks, but also when transmission is already high and health systems may be strained. Reducing risks associated with air travel could pave the way to air industry recovery, as well as offer relief to national economies and reduce social distress [63]. Efforts to control transmission before and after travel rely on individual mitigation measures such as mask use and social distancing before, during, and after travel, but additional control measures, such as testing and quarantine, have also been used by some countries. The fifth meeting of the International Health Regulations Emergency Committee convened by WHO regarding the COVID-19 pandemic stated that for health measures related to international travel, countries should regularly reappraise measures applied to international travel and ensure those measures (including targeted use of diagnostics and quarantine) are risk- and evidence-based [64].

Here, we used a mathematical model to assess the relative impact of three mitigation measures to reduce transmission risk from infected travelers: symptom monitoring, testing, and quarantine. We assessed combinations of these mitigation measures with different estimates of the infectious period, different estimates of test-positivity relative to time of infection, and different assumptions about infection timing and test sensitivity. We frame these results as proportional reductions in transmission risk from infected travelers during or after travel to consider the importance of optimizing mitigation measures to address peak infectiousness (Fig. 1a). On its own, quarantine was the most effective of the three strategies, with a 14-day quarantine almost eliminating risk and a 7-day quarantine being more effective than any single other measure. However, these measures can be more effective when used together. For example, symptom monitoring is relatively easy and further increases the effect of a 7-day quarantine to 88–98% with a 7-day exposure window prior to arrival (Fig. 4).

Testing also provides added benefit but is contingent on the timing and quality of the test. Testing prior to travel reduces transmission risk both while traveling and after travel if testing is done close to the time of travel. Testing closer to the time of travel is more likely to detect individuals who are infectious while traveling and immediately afterwards but can still miss infected travelers who are in their latent period, as they may not have enough viral shedding to be detected. While testing immediately prior to travel can substantially reduce risk, it poses additional logistical challenges: results must be reliably available prior to travel and protocols would be needed to effectively isolate individuals who test positive and their close contacts. On the other hand, testing more than 3 days before travel provides little benefit beyond what symptom monitoring can provide, because individuals who test positive at that point contribute less to transmission risk during and after travel than individuals who test negative because they are in their latent period or not yet infected at that time. Because of the value of testing close to the time of travel, a lower sensitivity test with faster results can be more effective despite decreased sensitivity. This finding is consistent with modeling work by Larremore et al. showing that limitations of reduced sensitivity can be overcome by more frequent testing that can still identify infections in time to reduce transmission, in this case, closer to the time of travel [65]. This conclusion draws attention to the importance of turnaround times to allow for corresponding decision-making, not just the sensitivity of the test. While test and setting-specific test turnaround times are critical to planning, they are highly varied and were not included here. These results should be considered in that context. For example, short turn-around time is very important for pre-travel testing but less critical for post-travel testing at days 3 or 4 when individuals are expected to remain in quarantine for 7 days or more.

In the absence of quarantine or with low adherence to quarantine, post-arrival testing is likely most effective 1–2 days after arrival, balancing early detection with optimal sensitivity for travelers in their latent period while traveling. With high-adherence quarantine or potential exposure closer to the time of travel (for example, while traveling), optimal post-arrival test timing is later, 5–6 days after travel. This corresponds to improved sensitivity for detecting individuals who may be infected close to the time of arrival and are most likely to be infectious at the end of the quarantine. With exposure up to 7 days prior to travel, we found that optimal test timing was on days 0–2 after arrival with symptom monitoring and no quarantine, days 5–6 with symptom monitoring and quarantine with 100% adherence, and days 0–3 with symptom monitoring and quarantine with 50% adherence. When exposure time is known more precisely or is specifically at the time of travel, for example with a high-risk contact while traveling or otherwise, the optimal test time is on days 4–5 after that exposure to optimize test sensitivity with or without symptom monitoring and on days 6–7 when combined with quarantine (Fig. 2). Beyond days 7–8 post-infection, the sensitivity for detecting infections in the models considered here begins to decrease (Fig. 1b). Even with quarantine measures in place, tests on or after arrival may have additional roles if quarantine adherence is imperfect or to assist in contact tracing when other travelers are potentially infected. Waiting to test several days after arrival improves the chance of detecting an individual who will

be infectious at the end of the quarantine but does not optimize early detection of other infections among travelers.

These results are generally consistent with other analyses of risk associated with travel. Early in the pandemic, it was apparent that symptom screening at airports or other transit hubs could not stop the spread of SARS-CoV-2 [18]. Using an individual-level simulation framework, Clifford et al. found that more than half of infected travelers would not be detected by exit and entry screening based on temperature measurement, observation for illness, and health declaration [51]. Sufficient detection of infected travelers to avoid uncontrolled importations is largely dependent on a set of assumptions that are inconsistent with COVID-19 epidemiology: asymptomatic transmission being negligible, very high airport symptom screening sensitivity, and a short incubation period. Clifford et al. also assessed combined measures and estimated that an 8-day quarantine period with an RT-PCR test on day 7 would be nearly as effective as a 14-day quarantine on its own. Other recent work highlights the effectiveness of shorter quarantine periods combined with testing for individuals with known exposures [53, 66, 67]. Across these studies, the specific days for quarantine or testing and the estimated effectiveness varied due to differences in assumptions about the time of exposure, different modeled test characteristics, and differences in parameters for the infectious period. Nonetheless, all indicate the value of shorter quarantine combined with symptom monitoring and testing, a finding that is helpful both in the travel setting and in other settings with exposure risk.

The model used here has some specific limitations. First, the infectious period of SARS-CoV-2 is not well-defined. We therefore considered multiple models of the infectious period generated by multiple approaches to reflect uncertainty around this period, yet these models also have limitations, are not exhaustive, and more detail is needed for more precise estimates. Moreover, each of the infectious period models captures only the average infectious period, so for individual travelers, this could be substantially different. The most effective measures modeled here are close to 100% effective in the model; however, the existence of individual-level variation suggests that none of these approaches would truly be 100% effective. Even with a 14-day quarantine, it is likely that some individuals will be infectious later, or even develop symptoms only at the end of the time period. Nonetheless, the average parameterization gives the expected average effectiveness for larger numbers of infected travelers; this is the scale at which policies may be most useful. Testing options are also highly varied and not well-characterized. The test options considered here are not exhaustive nor precisely characterized. Moreover, test turnaround time can also vary. We did not model test turnaround time; instead, we focused on when the test was performed, such that the result turnaround time could be considered in the context of whatever testing and laboratory resources are available. For example, a test during quarantine should be done sufficiently early so that results are available before the end of quarantine, but that delay varies in different settings. Our framework, however, can be applied with many other options, or with better characterized distributions as these become available.

We also did not consider behavioral aspects of prevention, with the exception of adherence to quarantine. For simplicity, we assumed that quarantine was equivalent to individual-level isolation and that symptomatic individuals or those testing positive are isolated immediately. However, individuals may quarantine with others. In that case, symptom onset or a positive test for a single individual can indicate exposure for the others during quarantine. Without symptom onset or a positive test, there may be silent secondary transmission that could result in additional post-quarantine risk. Moreover, travelers may have little incentive to consistently adhere to these measures, and notification or enforcement of them also would require substantial effort and resources. Some travelers could attribute symptoms to other etiologies, such as an exacerbation of a pre-existing condition or travel fatigue. Additionally, if negative test results are available prior to the recommended end of quarantine, individuals may be less likely to complete the recommended quarantine perceiving that the test is sufficient evidence of not being infected. While adherence to all measures may be lower in practice than considered here, the relative effectiveness of measures still provides a useful guide. Moreover, the effectiveness of shorter quarantines, especially when combined with symptom monitoring and testing, may be enhanced because a shorter quarantine is less onerous and may drive better adherence [68].

Finally, we focused on comparing the effectiveness of intervention measures for infected travelers, not the reduction in absolute risk as that varies by location and time. This is therefore not an analysis of the conditions in which these measures should be implemented, nor of the specific logistical and policy challenges that arise in different situations. Quarantine of all travelers can be an effective prevention measure but could also result in the restricted movement of many travelers who are not infected and, therefore, pose no risk. When the absolute risk of infection in travelers is low and the number of travelers is high, quarantine of travelers without symptoms would predominantly result in the quarantine of uninfected people. Testing is helpful in part because it

can reduce the length of quarantine needed for optimal prevention. However, testing can also result in false negatives (missed cases that are released from quarantine when still infectious) or false positives (individuals who test positive but are not actually infected). The impact of false positives can be partly mitigated by confirmatory testing. It is also possible that some recently recovered individuals will test positive but no longer be infectious (e.g., by RT-PCR which can detect SARS-CoV-2 RNA after the infectious period has ended). Additional testing or assessment of cycle threshold values may help reduce the impact on these individuals [69]. It is important that authorities also carefully consider prioritization of testing resources in the context of other public health needs in resource-limited situations.

A multi-layered approach is needed to control SARS-CoV-2 transmission associated with travel. Infection prevention measures (e.g., social distancing, mask use, hand hygiene, enhanced cleaning, and disinfection) are expected to reduce risk before, during, and after travel. Symptom monitoring, quarantine, and testing can all complement those measures to further reduce risk. Predeparture SARS-CoV-2 testing can supplement symptom monitoring to identify potentially infectious travelers who do not have symptoms, and therefore, offers an opportunity to further reduce transmission risk during and after travel. Post-arrival SARS-CoV-2 testing can identify asymptomatic or pre-symptomatic infected travelers, including some who may have tested negative prior to departure, if prior testing took place. Post-arrival testing is likely effective at days 1–2 without quarantine, but more effective later, at days 5–6, if combined with an effective quarantine of 7 days or longer. A 14-day quarantine is effective on its own but combined with testing and symptom monitoring (with isolation of those who develop symptoms or test positive), quarantine can be shortened and still be effective. These findings can inform policies for travel until safe and effective vaccines become widely available.

Acknowledgements
Not applicable

Authors' contributions
MAJ, PSD, THC, CMB, MSC, and FAR conceived the study. MAJ, HW, and PP designed and carried out the analyses. MAJ, HW, PP, PSD, and FAR drafted the manuscript. All authors revised the manuscript. The authors read and approved the final manuscript.

Funding
No specific funding source was used for this study.

Availability of data and materials
All code required to run the analysis is available at https://github.com/cdcepi/COVID-19-traveler-model.

Declarations

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Received: 19 January 2021 Accepted: 25 March 2021
Published online: 14 April 2021

References
1. Devi S. Travel restrictions hampering COVID-19 response. Lancet. 2020; 395(10233):1331–2. https://doi.org/10.1016/S0140-6736(20)30967-3.
2. Studdert DM, Hall MA, Mello MM. Partitioning the curve — interstate travel restrictions during the Covid-19 pandemic. N Engl J Med. 2020;383(13):e83. https://doi.org/10.1056/NEJMp2024274.
3. TSA checkpoint travel numbers for 2020 and 2019 | Transportation Security Administration. https://www.tsa.gov/coronavirus/passenger-throughput. Accessed 5 Nov 2020.
4. Air travel in the time of COVID-19. Lancet Infect Dis. 2020;20:993.
5. Maneenop S, Kotcharin S. The impacts of COVID-19 on the global airline industry: an event study approach. J Air Transp Manag. 2020;89:101920. https://doi.org/10.1016/j.jairtraman.2020.101920.
6. Sun X, Wandelt S, Zhang A. How did COVID-19 impact air transportation? A first peek through the lens of complex networks. J Air Transp Manag. 2020; 89:101928.
7. Forsyth P, Guiomard C, Niemeier H-M. Covid −19, the collapse in passenger demand and airport charges11The authors wish to thank Brian Pearce of IATA and Michael Stanton-Geddes of ACI for helpful discussions and data, and also two anonymous referees for their comments. J Air Transp Manag. 2020;89:101932. https://doi.org/10.1016/j.jairtraman.2020.101932.
8. Airlines Seek Gate Checks for Virus to Revive Foreign Travel. Bloomberg.com. 2020. https://www.bloomberg.com/news/articles/2020-09-09/airlines-seek-u-s-airport-virus-tests-to-revive-foreign-travel. Accessed 5 Nov 2020.
9. Wilson ME, Chen LH. Re-starting travel in the era of COVID-19: preparing anew. J Travel Med. 2020;27(5). https://doi.org/10.1093/jtm/taaa108.
10. US Department of Transportation. Runway to Recovery: The United States Framework for Airlines and Airports to Mitigate the Public Health Risks of Coronavirus, Guidance Jointly Issued by the U.S. Departments of Transportation, Homeland Security, and Health and Human Services. https://www.transportation.gov/sites/dot.gov/files/2020-07/Runway_to_Recovery_07022020.pdf. Accessed 5 Nov 2020.
11. Anderson SC, Mulberry N, Edwards AM, Stockdale JE, Iyaniwura SA, Falcao RC, et al. How much leeway is there to relax COVID-19 control measures? medRxiv. 2020. doi:https://doi.org/10.1101/2020.06.12.20129833.
12. Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of Persons who Pose a Risk of Transmitting 2019 Novel Coronavirus. The White House. https://www.whitehouse.gov/presidential-actions/proclamation-suspension-entry-immigrants-nonimmigrants-persons-pose-risk-transmitting-2019-novel-coronavirus/. Accessed 5 Nov 2020.
13. Linka K, Peirlinck M, Costabal FS, Kuhl E. Outbreak dynamics of COVID-19 in Europe and the effect of travel restrictions. Comput Methods Biomech Biomed Engin. 2020;23(11):710–7. https://doi.org/10.1080/10255842.2020.1759560.
14. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020;368(6489):395–400. https://doi.org/10.1126/science.aba9757.
15. Pombal R, Hosegood I, Powell D. Risk of COVID-19 during air travel. JAMA. 2020;324(17):1798. https://doi.org/10.1001/jama.2020.19108.
16. International Civil Aviation Organization Council Aviation Recovery Task Force. Take-off: guidance for air travel through the COVID-19 public health crisis. 2020. https://www.icao.int/covid/cart/Documents/CART_Report_Take-Off_Document.pdf. Accessed 5 Nov 2020.
17. Mouchtouri VA, Bogogiannidou Z, Dirksen-Fischer M, Tsiodras S, Hadjichristodoulou C. Detection of imported COVID-19 cases worldwide: early assessment of airport entry screening, 24 January until 17 February

2020. Trop Med Health. 2020;48(1):79. https://doi.org/10.1186/s41182-020-00260-5.
18. Gostic K, Gomez AC, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. eLife. 2020;9:e55570. https://doi.org/10.7554/eLife.55570.
19. Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK. European Centre for Disease Prevention and Control. 2020. https://www.ecdc.europa.eu/en/publications-data/passenger-locator-data-entry-exit-screening-health-declaration. Accessed 5 Nov 2020.
20. Vilke GM, Brennan JJ, Cronin AO, Castillo EM. Clinical features of patients with COVID-19: is temperature screening useful? J Emerg Med. 2020;59(6):952–6. https://doi.org/10.1016/j.jemermed.2020.09.048.
21. Dollard P. Risk Assessment and Management of COVID-19 Among Travelers Arriving at Designated U.S. Airports, January 17–September 13, 2020. MMWR Morb Mortal Wkly Rep. 2020;69. https://doi.org/10.15585/mmwr.mm6945a4.
22. Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection. Ann Intern Med. 2020;173(5):362–7. https://doi.org/10.7326/M20-3012.
23. Furukawa NW, Brooks JT, Sobel J. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while Presymptomatic or asymptomatic. Emerg Infect Dis. https://doi.org/10.3201/eid2607.201595.
24. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo. Nature. 2020;584(7821):425–9. https://doi.org/10.1038/s41586-020-2488-1.
25. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. Plos Med. 2020;17(9):e1003346. https://doi.org/10.1371/journal.pmed.1003346.
26. Joshi RK, Ray RK, Adhya S, Chauhan VPS, Pani S. Spread of COVID-19 by asymptomatic cases: evidence from military quarantine facilities. BMJ Mil Health. 2020:bmjmilitary-2020-001669. https://doi.org/10.1136/bmjmilitary-2020-001669.
27. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4(1):e2035057. https://doi.org/10.1001/jamanetworkopen.2020.35057.
28. Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for transmission of COVID-19 prior to symptom onset. eLife. 2020;9:e57149. https://doi.org/10.7554/eLife.57149.
29. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Int J Infect Dis. 2020;93:284–6. https://doi.org/10.1016/j.ijid.2020.02.060.
30. Zhao S, Gao D, Zhuang Z, Chong MKC, Cai Y, Ran J, et al. Estimating the serial interval of the novel coronavirus disease (COVID-19): a statistical analysis using the public data in Hong Kong from January 16 to February 15, 2020. Front Phys. 2020;8. https://doi.org/10.3389/fphy.2020.00347.
31. Wei WE. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69. https://doi.org/10.15585/mmwr.mm6914e1.
32. Tong Z-D, Tang A, Li K-F, Li P, Wang H-L, Yi J-P, et al. Potential Presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020;26(5):1052–4. https://doi.org/10.3201/eid2605.200198.
33. Considerations for quarantine of contacts of COVID-19 cases. https://www.who.int/publications-detail-redirect/considerations-for-quarantine-of-individuals-in-the-context-of-containment-for-coronavirus-disease-(covid-19). Accessed 5 Nov 2020.
34. Peak CM, Kahn R, Grad YH, Childs LM, Li R, Lipsitch M, et al. Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study. Lancet Infect Dis. 2020;20(9):1025–33. https://doi.org/10.1016/S1473-3099(20)30361-3.
35. Saldaña F, Flores-Arguedas H, Camacho-Gutiérrez JA, Barradas I. Modeling the transmission dynamics and the impact of the control interventions for the COVID-19 epidemic outbreak. Math Biosci Eng. 2020;17(4):4165–83. https://doi.org/10.3934/mbe.2020231.
36. Lin C, Mullen J, Braund WE, Tu P, Auerbach J. Reopening safely – Lessons from Taiwan's COVID-19 response. J Glob Health. 10. https://doi.org/10.7189/jogh.10.020318.
37. Lam HY, Lam TS, Wong CH, Lam WH, Leung CME, Au KWA, et al. The epidemiology of COVID-19 cases and the successful containment strategy in Hong Kong–January to may 2020. Int J Infect Dis. 2020;98:51–8. https://doi.org/10.1016/j.ijid.2020.06.057.
38. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. JAMA Netw Open. 2020;3(7):e2016818. https://doi.org/10.1001/jamanetworkopen.2020.16818.
39. Taylor T, Das R, Mueller K, Pransky G, Christian J, Orford R, et al. Safely returning America to work: part I: general guidance for employers. J Occup Environ Med. 2020;62(9):771–9. https://doi.org/10.1097/JOM.0000000000001984.
40. Murray MT. Mitigating a COVID-19 Outbreak Among Major League Baseball Players — United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69. https://doi.org/10.15585/mmwr.mm6942a4.
41. Coronavirus (COVID-19) Travel Restrictions By Country. KAYAK. https://www.kayak.com/travel-restrictions. Accessed 5 Nov 2020.
42. Visiting Iceland. https://www.covid.is/categories/tourists-travelling-to-iceland. Accessed 5 Nov 2020.
43. No. 205.2: Quarantine Restrictions on Travelers Arriving in New York. Governor Andrew M. Cuomo. 2020. https://www.governor.ny.gov/news/no-2052-quarantine-restrictions-travelers-arriving-new-york. Accessed 5 Nov 2020.
44. Centers for Medicare and Medicaid Services. What is CMS's policy regarding laboratories performing antigen tests authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) for use at the point of care (POC) or in patient care settings operating under a Clinical Laboratory Improvement Amendments of 1988 (CLIA) Certificate of Waiver on asymptomatic individuals? https://www.cms.gov/files/document/clia-poc-ag-test-enforcement-discretion.pdf. Accessed 5 Nov 2020.
45. Food and Drug Administration. Individual EUAs for Antigen Diagnostic Tests for SARS-CoV-2. FDA. 2020. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas. Accessed 5 Nov 2020.
46. Alemany A, Baró B, Ouchi D, Rodó P, Ubals M, Corbacho-Monné M, Vergara-Alert J, Rodon J, Segalés J, Esteban C, Fernández G, Ruiz L, Bassat Q, Clotet B, Ara J, Vall-Mayans M, G-Beiras C, Blanco I, Mitjà O. Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. J Inf Secur. 2021;0. https://doi.org/10.1016/j.jinf.2020.12.033.
47. Pilarowski G, Lebel P, Sunshine S, Liu J, Crawford E, Marquez C, et al. The CLIAHUB Consortium, DeRisi J. Performance characteristics of a rapid severe acute respiratory syndrome coronavirus 2 antigen detection assay at a public plaza testing site in San Francisco. J Infect Dis. 2021. https://doi.org/10.1093/infdis/jiaa802.
48. Prince-Guerra JL. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020. MMWR Morb Mortal Wkly Rep. 2021;70. https://doi.org/10.15585/mmwr.mm7003e3.
49. Pray IW. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020. MMWR Morb Mortal Wkly Rep. 2021;69. https://doi.org/10.15585/mmwr.mm695152a3.
50. Burns J, Movsisyan A, Stratil JM, Coenen M, Emmert-Fees KM, Geffert K, et al. Travel-related control measures to contain the COVID-19 pandemic: a rapid review. Cochrane Database Syst Rev. 2020. https://doi.org/10.1002/14651858.CD013717.
51. Clifford S, Quilty BJ, Russell TW, Liu Y, Chan Y-WD, Pearson CAB, et al. Strategies to reduce the risk of SARS-CoV-2 re-introduction from international travellers. medRxiv. 2020. https://doi.org/10.1101/2020.07.24.20161281.
52. Dickens BL, Koo JR, Lim JT, Sun H, Clapham HE, Wilder-Smith A, et al. Strategies at points of entry to reduce importation risk of COVID-19 cases and re-open travel. J Travel Med. 2020;27(8). https://doi.org/10.1093/jtm/taaa141.
53. Ashcroft P, Lehtinen S, Angst DC, Low N, Bonhoeffer S. Quantifying the impact of quarantine duration on COVID-19 transmission. medRxiv. 2020. https://doi.org/10.1101/2020.09.24.20201061.
54. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–5. https://doi.org/10.1038/s41591-020-0869-5.

55. Casey M, Griffin J, McAloon CG, Byrne AW, Madden JM, McEvoy D, et al. Pre-symptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published data. medRxiv. 2020. https://doi.org/10.1101/2020.05.08.20094870.
56. Benefield AE, Skrip LA, Clement A, Althouse RA, Chang S, Althouse BM. SARS-CoV-2 viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis of coronavirus viral load from 66 studies. medRxiv. 2020. https://doi.org/10.1101/2020.09.28.20202028.
57. Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Inf Secur. 2020;81:357–71.
58. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open. 2020;10(8):e039856. https://doi.org/10.1136/bmjopen-2020-039856.
59. Goyal A, Reeves DB, Cardozo-Ojeda EF, Schiffer JT, Mayer BT. Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events. medRxiv. 2020. https://doi.org/10.1101/2020.08.07.20169920.
60. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9. https://doi.org/10.1038/s41586-020-2196-x.
61. McAloon C, Collins Á, Hunt K, Barber A, Byrne AW, Butler F, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open. 2020;10(8):e039652. https://doi.org/10.1136/bmjopen-2020-039652.
62. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173(4):262–7. https://doi.org/10.7326/M20-1495.
63. Lamb TL, Winter SR, Rice S, Ruskin KJ, Vaughn A. Factors that predict passengers willingness to fly during and after the COVID-19 pandemic. J Air Transp Manag. 2020;89:101897. https://doi.org/10.1016/j.jairtraman.2020.101897.
64. Statement on the fifth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. https://www.who.int/news/item/30-10-2020-statement-on-the-fifth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic. Accessed 5 Nov 2020.
65. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. medRxiv. 2020. https://doi.org/10.1101/2020.06.22.20136309.
66. Quilty BJ, Clifford S, Group2 C nCoV working, Flasche S, Eggo RM. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). Euro Surveill. 2020;25:2000080.
67. Wells CR, Townsend JP, Pandey A, Krieger G, Singer B, McDonald RH, et al. Optimal COVID-19 quarantine and testing strategies. medRxiv. 2020. https://doi.org/10.1101/2020.10.27.20211631.
68. Webster RK, Brooks SK, Smith LE, Woodland L, Wessely S, Rubin GJ. How to improve adherence with quarantine: rapid review of the evidence. Public Health. 2020;182:163–9. https://doi.org/10.1016/j.puhe.2020.03.007.
69. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa638.

Publisher's Note

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Mon, 26 Dec 2022 19:01:40 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: IM slides_predeparture testing_final.pptx

Don't think we are updating the paper, this is for background for the call.

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Monday, December 26, 2022 1:43 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Thanks, Nicky!

Henry, are you tracking what needs to go to into the paper?

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Monday, December 26, 2022 1:41 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Nicky.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 1:23 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Subject: Re: IM slides_predeparture testing_final.pptx

Adding Nicky

Lisa Rotz MD
Acting Director,

Division of Global Migration and Quarantine, CDC

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:17:09 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: IM slides_predeparture testing_final.pptx

(b)(5)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:07:08 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

Fig. 3


A
Reduction in transmission risk (%)
0
20
40
60
80
100
Symp. monitoring
Test alone
Test + symp. monitoring
No test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)
B
Reduction in transmission risk (%)
0
20
40
60
80
100
95% sensitivity antigen test
80% sensitivity antigen test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)

Reductions in SARS-CoV-2 transmission during travel. **a** Reduction in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel, stratified by method of risk reduction. Individuals developing symptoms are assumed to be isolated and therefore do not travel. **b** Reductions in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel comparing the antigen assays with 80% and 95% sensitivity. Ranges indicate uncertainty from the different infectiousness models

---

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 1:01 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

This page has what you want



Fig. 2 Reductions in total average SARS-CoV-2 transmission risk after infection at a known high-risk exposure time (day 0) without considering travel. Transmission risk reductions are stratified by method of risk reduction including symptom monitoring, quarantine (7 or 14 days), and testing (test on days 1–7). Symptom monitoring is assumed to be ongoing regardless of the test date when implemented and either symptom onset or a positive test result is assumed to result in immediate isolation until the individual is no longer infectious. The bars represent the median estimates and the error bars show the ranges (minima and maxima) across the different infectiousness curves and test positivity curves (when testing was included)

effective at detecting infections; later testing means that while the test was more likely to be positive, the infectious period may begin prior to the test, leading to a smaller reduction in risk.

Combining symptom monitoring or quarantine with testing provided added benefit, leading to increased risk reduction, especially with a test at day 3–5 post-exposure with symptom monitoring (47–75% reduction with 30% never symptomatic or 39–73% with 50% never symptomatic) or a test at day 5–7 with a 7-day quarantine (76–95% reduction). A 7-day quarantine with symptom monitoring and a test at day 5–7 further increased the lower bound of likely risk reduction to 91–98% (with 30% never symptomatic, 86–97% with 50% never symptomatic). The effect of moderately different assumptions related to the proportion of infections that never result in symptoms had minimal impacts when symptom monitoring was combined with testing or quarantine, we therefore use the 30% value for this parameter in the following analyses.

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

We assessed the impact of test sensitivity relative to timing by comparing the antigen-type test model to the same model with higher sensitivity. With the same time-specific pattern but different sensitivity (80% vs. 95%, Fig. 3b), the higher sensitivity test gives a higher reduction in transmission risk if used at the same time. However, the importance of sensitivity is intertwined with timing. The lower sensitivity test was as effective or more effective than a higher sensitivity test if it was performed closer to the time of travel. For example, the test with 80% sensitivity performed 1 day prior to departure was 47–58% effective at reducing transmission risk during travel, while the test with 95% sensitivity performed 3 days prior to departure was 18–35% effective.

Transmission risk after travel

We then considered measures to reduce the risk of SARS-CoV-2 introduction to the destination location from travelers, i.e., transmission risk after traveling (Fig. 4). Assuming infection occurs at an unknown time within a 7-day exposure period prior to arrival (i.e., including possible infection while traveling), a single test on its own was most effective when performed 1- or 2-days post-arrival (29–53% and 29–51% reduction in transmission risk, respectively). This reduction in introduction risk was higher than reductions generated by

Cindy R. Friedman, MD

Chief, Travelers' Health Branch

Division of Global Migration and Quarantine

National Center for Emerging Zoonotic and Infectious Diseases

Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:49 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Thank you, (b)(5)

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 12:46 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:42 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Julia,

(b)(6) Can you work with Cindy to get the BLUF answer for Nancy K. question to add to the Sherri doc? (b)(5)

(b)(5)

L

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Monday, December 26, 2022 12:30 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: FW: IM slides_predeparture testing_final.pptx

Resending this to the top of your email box Henry. (b)(5)
(b)(5)
(b)(5) Cindy can confirm.

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 22, 2022 10:48 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: IM slides_predeparture testing_final.pptx

Henry,

Here are the slides from IM and an abstract for an upcoming mtg that is 90% cleared.
I would just highlight that we should (b)(5)

(b)(5)

Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Mon, 26 Dec 2022 17:35:01 +0000
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: IM slides_predeparture testing_final.pptx

Thank you Lisa, was just looking for it

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:30 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: FW: IM slides_predeparture testing_final.pptx

Resending this to the top of your email box Henry. (b)(5)

(b)(5)

(b)(5) Cindy can confirm.

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 22, 2022 10:48 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: IM slides_predeparture testing_final.pptx

Henry,

Here are the slides from IM and an abstract for an upcoming mtg that is 90% cleared.
I would just highlight that we should (b)(5)

(b)(5)

Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Mon, 26 Dec 2022 18:02:14 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Walke, Henry (CDC/DDPHSIS/CPR/OD); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ)
Subject: Re: IM slides_predeparture testing_final.pptx

Adding Nicky C since I also asked her to check the paper :)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 12:01:21 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

This page has what you want



Fig. 2 Reductions in total average SARS-CoV-2 transmission risk after infection at a known high-risk exposure time (day 0) without considering travel. Transmission risk reductions are stratified by method of risk reduction including symptom monitoring, quarantine (7 or 14 days), and testing (test on days 1–7). Symptom monitoring is assumed to be ongoing regardless of the test date when implemented and either symptom onset or a positive test result is assumed to result in immediate isolation until the individual is no longer infectious. The bars represent the median estimates and the error bars show the ranges (minima and maxima) across the different infectiousness curves and test positivity curves (when testing was included)

effective at detecting infections; later testing means that while the test was more likely to be positive, the infectious period may begin prior to the test, leading to a smaller reduction in risk.

Combining symptom monitoring or quarantine with testing provided added benefit, leading to increased risk reduction, especially with a test at day 3–5 post-exposure with symptom monitoring (47–75% reduction with 30% never symptomatic or 39–73% with 50% never symptomatic) or a test at day 5–7 with a 7-day quarantine (76–95% reduction). A 7-day quarantine with symptom monitoring and a test at day 5–7 further increased the lower bound of likely risk reduction to 91–98% (with 30% never symptomatic, 86–97% with 50% never symptomatic). The effect of moderately different assumptions related to the proportion of infections that never result in symptoms had minimal impacts when symptom monitoring was combined with testing or quarantine, we therefore use the 30% value for this parameter in the following analyses.

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

We assessed the impact of test sensitivity relative to timing by comparing the antigen-type test model to the same model with higher sensitivity. With the same time-specific pattern but different sensitivity (80% vs. 95%, Fig. 3b), the higher sensitivity test gives a higher reduction in transmission risk if used at the same time. However, the importance of sensitivity is intertwined with timing. The lower sensitivity test was as effective or more effective than a higher sensitivity test if it was performed closer to the time of travel. For example, the test with 80% sensitivity performed 1 day prior to departure was 47–58% effective at reducing transmission risk during travel, while the test with 95% sensitivity performed 3 days prior to departure was 18–35% effective.

Transmission risk after travel

We then considered measures to reduce the risk of SARS-CoV-2 introduction to the destination location from travelers, i.e., transmission risk after traveling (Fig. 4). Assuming infection occurs at an unknown time within a 7-day exposure period prior to arrival (i.e., including possible infection while traveling), a single test on its own was most effective when performed 1- or 2-days post-arrival (29–53% and 29–51% reduction in transmission risk, respectively). This reduction in introduction risk was higher than reductions generated by

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention

Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:49 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Thank you. (b)(5)

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 12:46 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:42 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Julia,

(b)(6) Can you work with Cindy to get the BLUF answer for Nancy K. question to add to the Sherri doc? (b)(5)

(b)(5)

(b)(5)

L

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Monday, December 26, 2022 12:30 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: FW: IM slides_predeparture testing_final.pptx

Resending this to the top of your email box Henry. (b)(5)

(b)(5)

(b)(5) Cindy can confirm.

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 22, 2022 10:48 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: IM slides_predeparture testing_final.pptx

Henry,

Here are the slides from IM and an abstract for an upcoming mtg that is 90% cleared.

I would just highlight that we should (b)(5)

(b)(5)

Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Mon, 26 Dec 2022 18:22:01 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Walke, Henry (CDC/DDPHSIS/CPR/OD); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ)
Subject: Re: IM slides_predeparture testing_final.pptx

True. So what can we say (b)(5)
(b)(5)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 12:19:32 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: IM slides_predeparture testing_final.pptx

those models were done pre omicron.
From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 1:17:09 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: IM slides_predeparture testing_final.pptx

(b)(5)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:07:08 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

Fig. 3


A
Reduction in transmission risk (%)
0
20
40
60
80
100
Symp. monitoring
Test alone
Test + symp. monitoring
No test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)
B
Reduction in transmission risk (%)
0
20
40
60
80
100
95% sensitivity antigen test
80% sensitivity antigen test
-6
-5
-4
-3
-2
-1
0
Time from test to departure (days)

Reductions in SARS-CoV-2 transmission during travel. **a** Reduction in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel, stratified by method of risk reduction. Individuals developing symptoms are assumed to be isolated and therefore do not travel. **b** Reductions in transmission risk during a 1-day trip assuming a 7-day exposure window prior to travel comparing the antigen assays with 80% and 95% sensitivity. Ranges indicate uncertainty from the different infectiousness models

---

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 1:01 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

This page has what you want



Fig. 2 Reductions in total average SARS-CoV-2 transmission risk after infection at a known high-risk exposure time (day 0) without considering travel. Transmission risk reductions are stratified by method of risk reduction including symptom monitoring, quarantine (7 or 14 days), and testing (test on days 1–7). Symptom monitoring is assumed to be ongoing regardless of the test date when implemented and either symptom onset or a positive test result is assumed to result in immediate isolation until the individual is no longer infectious. The bars represent the median estimates and the error bars show the ranges (minima and maxima) across the different infectiousness curves and test positivity curves (when testing was included)

effective at detecting infections; later testing means that while the test was more likely to be positive, the infectious period may begin prior to the test, leading to a smaller reduction in risk.

Combining symptom monitoring or quarantine with testing provided added benefit, leading to increased risk reduction, especially with a test at day 3–5 post-exposure with symptom monitoring (47–75% reduction with 30% never symptomatic or 39–73% with 50% never symptomatic) or a test at day 5–7 with a 7-day quarantine (76–95% reduction). A 7-day quarantine with symptom monitoring and a test at day 5–7 further increased the lower bound of likely risk reduction to 91–98% (with 30% never symptomatic, 86–97% with 50% never symptomatic). The effect of moderately different assumptions related to the proportion of infections that never result in symptoms had minimal impacts when symptom monitoring was combined with testing or quarantine, we therefore use the 30% value for this parameter in the following analyses.

Transmission risk during travel

To assess approaches for reducing risk of transmission while traveling, we assumed that exposure may have occurred at any time in the 7 days prior to departure and assessed reductions in transmission risk over a 1-day period following departure. Isolating individuals at the time of symptom onset prior to or during travel resulted in a 30–35% reduction in risk (Fig. 3a). Testing resulted in the greatest reduction of risk when the specimen was collected closest to the time of travel. Testing 3 days prior to travel resulted in a 10–29% reduction in transmission risk compared to a 44–72% reduction with testing on the day of travel. This was also true for testing combined with symptom monitoring, which had higher overall reductions.

We assessed the impact of test sensitivity relative to timing by comparing the antigen-type test model to the same model with higher sensitivity. With the same time-specific pattern but different sensitivity (80% vs. 95%, Fig. 3b), the higher sensitivity test gives a higher reduction in transmission risk if used at the same time. However, the importance of sensitivity is intertwined with timing. The lower sensitivity test was as effective or more effective than a higher sensitivity test if it was performed closer to the time of travel. For example, the test with 80% sensitivity performed 1 day prior to departure was 47–58% effective at reducing transmission risk during travel, while the test with 95% sensitivity performed 3 days prior to departure was 18–35% effective.

Transmission risk after travel

We then considered measures to reduce the risk of SARS-CoV-2 introduction to the destination location from travelers, i.e., transmission risk after traveling (Fig. 4). Assuming infection occurs at an unknown time within a 7-day exposure period prior to arrival (i.e., including possible infection while traveling), a single test on its own was most effective when performed 1- or 2-days post-arrival (29–53% and 29–51% reduction in transmission risk, respectively). This reduction in introduction risk was higher than reductions generated by

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention

Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 12:49 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Thank you, (b)(5)

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 12:46 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 12:42 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: IM slides_predeparture testing_final.pptx

Julia,

(b)(6) Can you work with Cindy to get the BLUF answer for Nancy K. question to add to the Sherri doc? (b)(5)

(b)(5)

(b)(5)

L

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Monday, December 26, 2022 12:30 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: FW: IM slides_predeparture testing_final.pptx

Resending this to the top of your email box Henry. (b)(5)

(b)(5)

(b)(5) Cindy can confirm.

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 22, 2022 10:48 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: IM slides_predeparture testing_final.pptx

Henry,

Here are the slides from IM and an abstract for an upcoming mtg that is 90% cleared.

I would just highlight that we should (b)(5)

(b)(5)

Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Tue, 27 Dec 2022 18:33:46 +0000
To: Novak, Ryan (CDC/DDID/NCIRD/DBD)
Cc: Berger, Sherri (CDC/OD/OCS); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Info on new China sequences uploaded 25-26Dec

Great news!

From: Novak, Ryan (CDC/DDID/NCIRD/DBD) <bnk4@cdc.gov>
Sent: Tuesday, December 27, 2022 1:20 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Info on new China sequences uploaded 25-26Dec

Following our call with China CDC on Friday 23-Dec, which included Xu Wenbo the Director of China CDC Institute of Viral Diseases, 91 new sequences were deposited to GISAID from China on 25Dec (n=25) & 26Dec (n=66).

- Collection dates between September 27 – December 24, 2022;
- Out of the 91 sequences, 42 sequences were BA.5.2 and 29 sequences were BF.7;
- Beijing and Fujian are reported the greatest number of sequences, followed by Guangdong, Inner Mongolia, and Sichuan;
- Additional sequence meta data, 60% of were done via Nasopharyngeal swab, 40% via Oropharyngeal swab.

Ryan Novak, PhD | CAPT, U.S. Public Health Service
CGH COVID-19 Responsible Official
bnk4@cdc.gov | 404-992-2512

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Fri, 30 Dec 2022 13:27:55 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Input needed: pre and post flight COVID testing

In my 1:3 with Dan/Deb on Monday, (b)(5)

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Friday, December 30, 2022 8:22 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

Oh, no, I know and agree!!!!!! Sorry if I confused things— (b)(5)
(b)(5) No question about that!

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Friday, December 30, 2022 8:21 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Friday, December 30, 2022 8:15 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

Right! That's what I mean—sorry, coffee hasn't kicked in. (b)(5)

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Friday, December 30, 2022 8:14 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP)

<zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Friday, December 30, 2022 8:07 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Friday, December 30, 2022 7:41 AM
To: Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

Thanks. (b)(5)

From: Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>
Sent: Thursday, December 29, 2022 3:54 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

Thanks, Lisa. Actually, (b)(5)

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Thursday, December 29, 2022 3:44 PM

To: Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

Hi Jay,
For the Traveler Genomic Surveillance program that collects samples form travelers - 2 swab samples are collected from arriving international travelers who participate in the voluntary program, one swab is pool tested the extra swab samples from the positive pools are sent to a partner lab for individual testing and strain characterization. Data is uploaded to GISAID , shared on COVID DATA Tracker and (b)(5)

(b)(5)

Cindy can correct or add further clarification on that part of what we're doing for collecting, characterizing, and sharing strain data on travelers to the US from various global locations. Defer to (b)(5)

L

From: Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>
Sent: Thursday, December 29, 2022 3:09 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: FW: Input needed: pre and post flight COVID testing

FYSA, some of the IDSA chatter. However, the question about what we do with the genomic surveillance data is valid—what is our plan?

Sent: Thursday, December 29, 2022 12:01 PM
To: Babcock, Hilary <hbabcock@wustl.edu>; Elisa Choi, MD, FACP, FIDSA <(b)(6)>; Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu>
Cc: Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Briggs, Eli <EBriggs@idsociety.org>; Aziz, Rabita <raziz@idsociety.org>; Branche, Angela <angela_branche@urmc.rochester.edu>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Cox, Lisa <lcox@idsociety.org>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek, Amanda <ajezek@idsociety.org>; Rexach, PhD, Carmen (b)(6); Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine <(b)(6)>; Foote, Mary (CDC health.nyc.gov) <mfootemd@health.nyc.gov>; Foster, Monique Aaron (CDC/DDPHSIS/CGH/DGHP) <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa (b)(6) Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia

(b)(6)
Subject: Re: Input needed: pre and post flight COVID testing

Agree. Pre-departure testing not likely to make much difference and no plan for how we are going to do anything differently if VOC identified. Post- arrival screening would make more sense theoretically, but not a viable option IMO given inability to do properly. Also agree that it doesn't make sense given we are not doing much to limit the ongoing burden of CoV-19 in US despite several things that could likely help, and as mentioned, no real response to XBBs spreading. Defunded national CoV response, no push for better vaccines or therapeutics, tepid making guidance, no indoor air standards. Etc.

Jeffrey S. Duchin, MD (he/him)
Health Officer, Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave, Suite 1250, Seattle, WA 98104
Tel: (206) 296-4774; Direct: (206) 263-8171; Fax: (206) 296-4803
E-mail: jeff.duchin@kingcounty.gov

From: Babcock, Hilary <hbabcock@wustl.edu>
Sent: Thursday, December 29, 2022 8:43:34 AM
To: Elisa Choi, MD, FACP, FIDSA <(b)(6); Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu>
Cc: Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Briggs, Eli <EBriggs@idsociety.org>; Aziz, Rabita <raziz@idsociety.org>; Branche, Angela <angela_branche@urmc.rochester.edu>; Butler, Jay <jcb3@cdc.gov>; Cox, Lisa <lcox@idsociety.org>; Duchin, Jeff <Jeff.Duchin@kingcounty.gov>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek, Amanda <ajezek@idsociety.org>; Rexach, PhD, Carmen <(b)(6); Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine <(b)(6); Foote, Mary <mfootemd@health.nyc.gov>; Foster, Monique <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa <(b)(6); Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia <(b)(6)
Subject: RE: Input needed: pre and post flight COVID testing

[EXTERNAL Email Notice!] External communication is important to us. Be cautious of phishing attempts. Do not click or open suspicious links or attachments.

agree

From: Elisa Choi, MD, FACP, FIDSA <(b)(6)
Sent: Thursday, December 29, 2022 10:40 AM
To: Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu>
Cc: Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Briggs, Eli <EBriggs@idsociety.org>; Aziz, Rabita <raziz@idsociety.org>; Babcock, Hilary <hbabcock@wustl.edu>; Branche, Angela <angela_branche@urmc.rochester.edu>; Butler, Jay <jcb3@cdc.gov>; Cox, Lisa <lcox@idsociety.org>; Duchin, MD, Jeffrey <jeff.duchin@kingcounty.gov>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek,

Amanda <ajezek@idsociety.org>; Rexach, PhD, Carmen (b)(6); Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine (b)(6); Foote, Mary <mfootemd@health.nyc.gov>; Foster, Monique <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa (b)(6); Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia (b)(6)

Subject: Re: Input needed: pre and post flight COVID testing

*** External Email - Caution ***

Agree with Sarah and Josh.

Also, I have grave concerns about this policy activating (or re-activating, would be more accurate) the odious and loathsome anti Asian sentiments, racism, and harassment, that has been an ugly byproduct of the racializing of COVID-19 during this pandemic.

I, and many others in the Pan Asian community, have had personal experiences with anti-Asian targeting, during this COVID-19 pandemic.

We don't need yet another politically motivated policy to stoke more anti Asian racist sentiments. Hate crimes against Asians have never been as high as they have been during COVID-19.

What is the rationale for uniquely singling out China with this policy? Is that evidence based, and grounded in medical/scientific rationale, or is it "politics"?

By the way, my views here only represent my own personal, albeit strongly held, beliefs, and are not meant to represent any organizational policy or statements.

(Please excuse brevity, typos, or other errors due to voice transcription and/or mobile messaging.)

Best regards,
Elisa Choi, MD, FACP, FIDSA (She/Her)
Internal Medicine / HIV Medicine / Infectious Diseases
Chair, Board of Governors - American College of Physicians (ACP)
Executive Committee, Board of Regents - American College of Physicians (ACP)

Public Health Committee, Member - Infectious Disease Society of America (IDSA)

No need to reply to my emails after hours or on the weekends.

Social Media:

Twitter: **@DrElisaChoi**

Instagram: **@drelisachoi**

Facebook: Dr. Elisa Choi, MD, FACP, FIDSA

On Thu, Dec 29, 2022 at 11:17 AM Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu> wrote:
I second Sarah's comments. The US (likely) has higher rates of infection than China. This policy seems like some political ploy rather than reasonable public health policy. There is little to no data to suggest that a travel restriction will do anything except to fuel anti-Asian hate, especially since we can't get our own damn country to wear a mask.

JB

Joshua Barocas, MD
Associate Professor of Medicine
University of Colorado School of Medicine, Divisions of General Internal Medicine and Infectious Diseases
12631 E. 17th Ave., Mailstop B180
Aurora CO, 80045
Joshua.Barocas@CUAnschutz.edu
@jabarocas
He/him/his

***I value your response to my emails, but I also value your well-being. Please do not feel compelled to respond to this message after usual work hours or on weekends or holidays.**

From: "Lim, Sarah (MDH)" <Sarah.Lim@state.mn.us>
Date: Thursday, December 29, 2022 at 8:06 AM
To: "Briggs, Eli" <EBriggs@idsociety.org>, "Aziz, Rabita" <raziz@idsociety.org>, "Babcock, MD, Hilary M." <hbabcock@dom.wustl.edu>, "Barocas, Joshua"

<JOSHUA.BAROCAS@CUANSCHUTZ.EDU>, "Branche, Angela" <angela_branche@urmc.rochester.edu>, "Butler, Jay" <jcb3@cdc.gov>, "Choi, Elisa" <(b)(6)>, "Cox, Lisa" <lcox@idsociety.org>, "Duchin, MD, Jeffrey" <jeff.duchin@kingcounty.gov>, "Hoopchuk, Sara" <shoopchuk@idsociety.org>, "Jezek, Amanda" <ajezek@idsociety.org>, "Rexach, PhD, Carmen" <(b)(6)> "Shane, MD, Andrea L." <ashane@emory.edu>, "Shoyinka, Adenike" <ashoyinka@ingham.org>, "Suresh G. Joshi" <sgj24@drexel.edu>, "Wark, Kellie" <kwark@kumc.edu>, "Weddle, Andrea" <aweddle@hivma.org>, "Butt, Adeel Ajwad" <aab2005@qatar-med.cornell.edu>, "Danko, Janine" <(b)(6)> "Foote, Mary" <mfootemd@health.nyc.gov>, "Foster, Monique" <ydg9@cdc.gov>, "Khuri-Bulos, MD, Najwa" <najwa.khuri@gmail.com>, "Rebollado, Paulina" <preboll@emory.edu>, "Smith, Helen" <HSmith@idsociety.org>, "Torriani, Francesca" <ftorriani@ucsd.edu>, "Turner, Cynthia" <(b)(6)>
Subject: Re: Input needed: pre and post flight COVID testing

[External Email - Use Caution]

I think if we have learned anything at all since 2020, it is that viruses, and variants, are going to spread regardless of travel restrictions. We know people will travel while incubating, travel via 3rd countries, travel from other countries with outbreaks, and so on.
The question I have regarding this testing requirement is why? What are we trying to achieve? Surveillance for new variants by testing arriving passengers as described in the article makes sense - we need to know what's circulating and whether it's more immune evasive, treatment evasive etc, especially if China is not doing that - but if we can't even ask the US population to wear a mask indoors or on public transit, saying these restrictions will help to reduce viral spread does not make sense. Seems like best case scenario, this might delay the arrival of a new variant by a few weeks, but perhaps CDC feels that is worth the effort.
Sarah

From: Briggs, Eli <EBriggs@idsociety.org>
Sent: Thursday, December 29, 2022 7:59 AM
To: Aziz, Rabita <raziz@idsociety.org>; Babcock, MD, Hilary M. <hbabcock@dom.wustl.edu>; Barocas, Joshua <Joshua.Barocas@CUAnschutz.edu>; Branche, Angela <angela_branche@urmc.rochester.edu>; Briggs, Eli <EBriggs@idsociety.org>; Butler, Jay <jcb3@cdc.gov>; Choi, Elisa <(b)(6)>; Cox, Lisa <lcox@idsociety.org>; Duchin, MD, Jeffrey <jeff.duchin@kingcounty.gov>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek, Amanda <ajezek@idsociety.org>; Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Rexach, PhD, Carmen <(b)(6)>; Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine <(b)(6)>; Foote, Mary <mfootemd@health.nyc.gov>; Foster, Monique <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa <(b)(6)>; Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia <(b)(6)>
Subject: Input needed: pre and post flight COVID testing

Good morning,

Apologies for interrupting your holiday period. You are likely aware of the recent policy change requiring travelers from China to the US to show a negative COVID-19 test. (See STATNews article quoting IDSA president.)

IDSA is seeking to put out a statement next week addressing the pros and cons of pre and post flight COVID-19 testing. Your input by **COB January 3** would be appreciated.

Thanks,

Happy new year!

-Eli

Eli Briggs, MA | Director of Public Policy
Infectious Diseases Society of America
ebriggs@idsociety.org
www.idsociety.org

Learn more at valueofid.org

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Thu, 29 Dec 2022 20:24:23 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Input needed: pre and post flight COVID testing

What does CDC do with the strain data that is collected through this program ? I know that CDC uploads the data in the genomic bank but is there a published weekly or other interval report on strains. Do we publish anything that indicates what strains we're isolating from travelers from different regions or is that just internal?

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 3:16 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Input needed: pre and post flight COVID testing

I had one call w Jay about (b)(5)

(b)(5)

Happy to answer questions

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Thursday, December 29, 2022 3:12 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: FW: Input needed: pre and post flight COVID testing

Cindy do you want to summarize what the TGS program and CDC does with the strain data in regards to monitoring and sharing the data externally then we can send back to Jay? Wondering if he's had a briefing on the TGS and if not if that would be helpful. What do you think Dan?

From: Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>
Sent: Thursday, December 29, 2022 3:09 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Mahon, Barbara (CDC/DDID/NCIRD/OD) <bdm3@cdc.gov>

Cc: Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Romero, Jose (CDC/DDID/NCIRD/OD) <yod8@cdc.gov>
Subject: FW: Input needed: pre and post flight COVID testing

FYSA, some of the IDSA chatter. However, the question about what we do with the genomic surveillance data is valid—what is our plan?

Sent: Thursday, December 29, 2022 12:01 PM
To: Babcock, Hilary <hbabcock@wustl.edu>; Elisa Choi, MD, FACP, FIDSA <(b)(6)>; Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu>
Cc: Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Briggs, Eli <EBriggs@idsociety.org>; Aziz, Rabita <raziz@idsociety.org>; Branche, Angela <angela_branche@urmc.rochester.edu>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Cox, Lisa <lcox@idsociety.org>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek, Amanda <ajezek@idsociety.org>; Rexach, PhD, Carmen <(b)(6)>; Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine <(b)(6)>; Foote, Mary (CDC health.nyc.gov) <mfootemd@health.nyc.gov>; Foster, Monique Aaron (CDC/DDPHSIS/CGH/DGHP) <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa <(b)(6)>; Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia <(b)(6)>
Subject: Re: Input needed: pre and post flight COVID testing

Agree. Pre-departure testing not likely to make much difference and no plan for how we are going to do anything differently if VOC identified. Post- arrival screening would make more sense theoretically, but not a viable option IMO given inability to do properly. Also agree that it doesn't make sense given we are not doing much to limit the ongoing burden of CoV-19 in US despite several things that could likely help, and as mentioned, no real response to XBBs spreading. Defunded national CoV response, no push for better vaccines or therapeutics, tepid making guidance, no indoor air standards. Etc.

Jeffrey S. Duchin, MD (he/him)
Health Officer, Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave, Suite 1250, Seattle, WA 98104
Tel: (206) 296-4774; Direct: (206) 263-8171; Fax: (206) 296-4803
E-mail: jeff.duchin@kingcounty.gov

From: Babcock, Hilary <hbabcock@wustl.edu>
Sent: Thursday, December 29, 2022 8:43:34 AM
To: Elisa Choi, MD, FACP, FIDSA <(b)(6)> Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu>
Cc: Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Briggs, Eli <EBriggs@idsociety.org>; Aziz, Rabita <raziz@idsociety.org>; Branche, Angela <angela_branche@urmc.rochester.edu>; Butler, Jay <jcb3@cdc.gov>; Cox, Lisa <lcox@idsociety.org>; Duchin, Jeff <Jeff.Duchin@kingcounty.gov>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek, Amanda <ajezek@idsociety.org>; Rexach, PhD, Carmen

(b)(6); Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine (b)(6); Foote, Mary <mfootemd@health.nyc.gov>; Foster, Monique <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa (b)(6); Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia (b)(6)
Subject: RE: Input needed: pre and post flight COVID testing

agree

From: Elisa Choi, MD, FACP, FIDSA (b)(6)
Sent: Thursday, December 29, 2022 10:40 AM
To: Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu>
Cc: Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Briggs, Eli <EBriggs@idsociety.org>; Aziz, Rabita <raziz@idsociety.org>; Babcock, Hilary <hbabcock@wustl.edu>; Branche, Angela <angela_branche@urmc.rochester.edu>; Butler, Jay <jcb3@cdc.gov>; Cox, Lisa <lcox@idsociety.org>; Duchin, MD, Jeffrey <jeff.duchin@kingcounty.gov>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek, Amanda <ajezek@idsociety.org>; Rexach, PhD, Carmen (b)(6); Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine (b)(6); Foote, Mary <mfootemd@health.nyc.gov>; Foster, Monique <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa (b)(6); Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia (b)(6)
Subject: Re: Input needed: pre and post flight COVID testing

Agree with Sarah and Josh.

Also, I have grave concerns about this policy activating (or re-activating, would be more accurate) the odious and loathsome anti Asian sentiments, racism, and harassment, that has been an ugly byproduct of the racializing of COVID-19 during this pandemic.

I, and many others in the Pan Asian community, have had personal experiences with anti-Asian targeting, during this COVID-19 pandemic.

We don't need yet another politically motivated policy to stoke more anti Asian racist sentiments. Hate crimes against Asians have never been as high as they have been during COVID-19.

What is the rationale for uniquely singling out China with this policy? Is that evidence based, and grounded in medical/scientific rationale, or is it "politics"?

By the way, my views here only represent my own personal, albeit strongly held, beliefs, and are not meant to represent any organizational policy or statements.

(Please excuse brevity, typos, or other errors due to voice transcription and/or mobile messaging.)

Best regards,
Elisa Choi, MD, FACP, FIDSA (She/Her)
Internal Medicine / HIV Medicine / Infectious Diseases
Chair, Board of Governors - American College of Physicians (ACP)
Executive Committee, Board of Regents - American College of Physicians (ACP)

Public Health Committee, Member - Infectious Disease Society of America (IDSA)

No need to reply to my emails after hours or on the weekends.

Social Media:

Twitter: **@DrElisaChoi**

Instagram: **@drelisachoi**

Facebook: Dr. Elisa Choi, MD, FACP, FIDSA

On Thu, Dec 29, 2022 at 11:17 AM Barocas, Joshua <JOSHUA.BAROCAS@cuanschutz.edu> wrote:
I second Sarah's comments. The US (likely) has higher rates of infection than China. This policy seems like some political ploy rather than reasonable public health policy. There is little to no data to suggest that a travel restriction will do anything except to fuel anti-Asian hate, especially since we can't get our own damn country to wear a mask.

JB

Joshua Barocas, MD
Associate Professor of Medicine

University of Colorado School of Medicine, Divisions of General Internal Medicine and Infectious Diseases
12631 E. 17th Ave., Mailstop B180
Aurora CO, 80045
Joshua.Barocas@CUAnschutz.edu
@jabarocas
He/him/his

***I value your response to my emails, but I also value your well-being. Please do not feel compelled to respond to this message after usual work hours or on weekends or holidays.**

From: "Lim, Sarah (MDH)" <Sarah.Lim@state.mn.us>
Date: Thursday, December 29, 2022 at 8:06 AM
To: "Briggs, Eli" <EBriggs@idsociety.org>, "Aziz, Rabita" <raziz@idsociety.org>, "Babcock, MD, Hilary M." <hbabcock@dom.wustl.edu>, "Barocas, Joshua" <JOSHUA.BAROCAS@CUANSCHUTZ.EDU>, "Branche, Angela" <angela_branche@urmc.rochester.edu>, "Butler, Jay" <jcb3@cdc.gov>, "Choi, Elisa" <(b)(6)>, "Cox, Lisa" <lcox@idsociety.org>, "Duchin, MD, Jeffrey" <jeff.duchin@kingcounty.gov>, "Hoopchuk, Sara" <shoopchuk@idsociety.org>, "Jezek, Amanda" <ajezek@idsociety.org>, "Rexach, PhD, Carmen" <(b)(6)>, "Shane, MD, Andrea L." <ashane@emory.edu>, "Shoyinka, Adenike" <ashoyinka@ingham.org>, "Suresh G. Joshi" <sgj24@drexel.edu>, "Wark, Kellie" <kwark@kumc.edu>, "Weddle, Andrea" <aweddle@hivma.org>, "Butt, Adeel Ajwad" <aab2005@qatar-med.cornell.edu>, "Danko, Janine" <(b)(6)>, "Foote, Mary" <mfootemd@health.nyc.gov>, "Foster, Monique" <ydg9@cdc.gov>, "Khuri-Bulos, MD, Najwa" <(b)(6)>, "Rebollado, Paulina" <preboll@emory.edu>, "Smith, Helen" <HSmith@idsociety.org>, "Torriani, Francesca" <ftorriani@ucsd.edu>, "Turner, Cynthia" <(b)(6)>
Subject: Re: Input needed: pre and post flight COVID testing

[External Email - Use Caution]

I think if we have learned anything at all since 2020, it is that viruses, and variants, are going to spread regardless of travel restrictions. We know people will travel while incubating, travel via 3rd countries, travel from other countries with outbreaks, and so on.
The question I have regarding this testing requirement is why? What are we trying to achieve? Surveillance for new variants by testing arriving passengers as described in the article makes sense - we need to know what's circulating and whether it's more immune evasive, treatment evasive etc, especially if China is not doing that - but if we can't even ask the US population to wear a mask indoors or on public transit, saying these restrictions will help to reduce viral spread does not make sense. Seems like best case scenario, this might delay the arrival of a new variant by a few weeks, but perhaps CDC feels that is worth the effort.
Sarah

From: Briggs, Eli <EBriggs@idsociety.org>
Sent: Thursday, December 29, 2022 7:59 AM

To: Aziz, Rabita <raziz@idsociety.org>; Babcock, MD, Hilary M. <hbabcock@dom.wustl.edu>; Barocas, Joshua <Joshua.Barocas@CUAnschutz.edu>; Branche, Angela <angela_branche@urmc.rochester.edu>; Briggs, Eli <EBriggs@idsociety.org>; Butler, Jay <jcb3@cdc.gov>; Choi, Elisa (b)(6); Cox, Lisa <lcox@idsociety.org>; Duchin, MD, Jeffrey <jeff.duchin@kingcounty.gov>; Hoopchuk, Sara <shoopchuk@idsociety.org>; Jezek, Amanda <ajezek@idsociety.org>; Lim, Sarah (MDH) <Sarah.Lim@state.mn.us>; Rexach, PhD, Carmen <(b)(6); Shane, MD, Andrea L. <ashane@emory.edu>; Shoyinka, Adenike <ashoyinka@ingham.org>; Suresh G. Joshi <sgj24@drexel.edu>; Wark, Kellie <kwark@kumc.edu>; Weddle, Andrea <aweddle@hivma.org>; Butt, Adeel Ajwad <aab2005@qatar-med.cornell.edu>; Danko, Janine <(b)(6); Foote, Mary <mfootemd@health.nyc.gov>; Foster, Monique <ydg9@cdc.gov>; Khuri-Bulos, MD, Najwa (b)(6) Rebollado, Paulina <preboll@emory.edu>; Smith, Helen <HSmith@idsociety.org>; Torriani, Francesca <ftorriani@ucsd.edu>; Turner, Cynthia (b)(6)
Subject: Input needed: pre and post flight COVID testing

Good morning,

Apologies for interrupting your holiday period. You are likely aware of the recent policy change requiring travelers from China to the US to show a negative COVID-19 test. (See STATNews article quoting IDSA president.)

IDSA is seeking to put out a statement next week addressing the pros and cons of pre and post flight COVID-19 testing. Your input by **COB January 3** would be appreciated.

Thanks,

Happy new year!

-Eli

Eli Briggs, MA | Director of Public Policy
Infectious Diseases Society of America
ebriggs@idsociety.org
www.idsociety.org

Learn more at valueofid.org

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Thu, 29 Dec 2022 21:12:05 +0000
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Subject: Re: JFK terminal 1

Agree, let's

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Thursday, December 29, 2022 4:06:50 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: JFK terminal 1

Either way, I think (b)(5)

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Thursday, December 29, 2022 3:57 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: Fwd: JFK terminal 1

(b)(5)

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android

From: Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>
Sent: Thursday, December 29, 2022 3:50:18 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: JFK terminal 1

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 3:47 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: JFK terminal 1

Ian can provide this info

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Thursday, December 29, 2022 3:45:54 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: JFK terminal 1

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 3:32 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: JFK terminal 1

(b)(5)

C

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Thursday, December 29, 2022 3:27 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: JFK terminal 1

(b)(5)

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 2:54:01 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: JFK terminal 1

Hi Henry,
I think (b)(5)

(b)(5)

Here is the press announcement and quote from the Governor
https://www.governor.ny.gov/news/governor-hochul-announces-groundbreaking-95-billion-new-terminal-one-major-step-forward-port

Our state-of-the-art renovations of New York State's airports are critical and long overdue - especially at JFK, the nation's front door to the world.
Governor Kathy Hochul

Let me know if you can help
Thanks
Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Thu, 29 Dec 2022 20:36:54 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ)
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD); Ruskey, Ian (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: Re: JFK terminal 1

(b)(5)

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 3:31:46 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: JFK terminal 1

(b)(5)

C
Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Thursday, December 29, 2022 3:27 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: JFK terminal 1

(b)(5)

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 2:54:01 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: JFK terminal 1

Hi Henry,
I think (b)(5)

(b)(5)

Here is the press announcement and quote from the Governor
https://www.governor.ny.gov/news/governor-hochul-announces-groundbreaking-95-billion-new-terminal-one-major-step-forward-port

Our state-of-the-art renovations of New York State's airports are critical and long overdue - especially at JFK, the nation's front door to the world.
Governor Kathy Hochul

Let me know if you can help
Thanks
Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Thu, 29 Dec 2022 21:15:11 +0000
To: Ruskey, Ian (CDC/DDID/NCEZID/DGMQ); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: Re: JFK terminal 1

(b)(5)

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>
Sent: Thursday, December 29, 2022 3:50:18 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: JFK terminal 1

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 3:47 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: JFK terminal 1

Ian can provide this info

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Thursday, December 29, 2022 3:45:54 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: JFK terminal 1

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 3:32 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>

Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: JFK terminal 1

(b)(5)

C

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Thursday, December 29, 2022 3:27 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: JFK terminal 1

(b)(5)

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Thursday, December 29, 2022 2:54:01 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: JFK terminal 1

Hi Henry,
I think (b)(5)

(b)(5)

(b)(5)

Here is the press announcement and quote from the Governor
https://www.governor.ny.gov/news/governor-hochul-announces-groundbreaking-95-billion-new-terminal-one-major-step-forward-port

Our state-of-the-art renovations of New York State's airports are critical and long overdue - especially at JFK, the nation's front door to the world.
Governor Kathy Hochul

Let me know if you can help
Thanks
Cindy

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 18:36:52 +0000
To: Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Chen, Tai-Ho (CDC/DDPHSIS/CPR/DSLR); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ); Parcels, Linde (CDC/DDPHSIS/CPR/OD); Byrkit, Ramona (CDC/DDPHSIS/CPR/DSLR); Nett, Randall J. (CDC/DDID/NCEZID/DVBD); Tackett, Brittany (CDC/DDPHSIS/CPR/OD); Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO)
Subject: RE: meeting asap to discuss travel updates/requirements from China

We have a call with industry at 2pm so can only be on for a brief call with you

-----Original Appointment-----
From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov> **On Behalf Of** Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR)
Sent: Wednesday, December 28, 2022 1:31 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: Fwd: meeting asap to discuss travel updates/requirements from China
When: Wednesday, December 28, 2022 1:30 PM-2:30 PM (UTC-05:00) Eastern Time (US & Canada).
Where: Microsoft Teams Meeting

From: Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR) <htv4@cdc.gov>
Sent: Wednesday, December 28, 2022 12:28:33 PM
To: Chen, Tai-Ho (CDC/DDPHSIS/CPR/DSLR) <tdc5@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Parcels, Linde (CDC/DDPHSIS/CPR/OD) <oqj1@cdc.gov>; Byrkit, Ramona (CDC/DDPHSIS/CPR/DSLR) <qpa1@cdc.gov>; Nett, Randall J. (CDC/DDID/NCEZID/DVBD) <gge5@cdc.gov>; Tackett, Brittany (CDC/DDPHSIS/CPR/OD) <nyu3@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: meeting asap to discuss travel updates/requirements from China
When: Wednesday, December 28, 2022 12:30 PM-1:30 PM.
Where: Microsoft Teams Meeting

Hi all and sorry for the quick meeting- Henry Walke called about the China situation. Can we meet asap to discuss? Moving quickly.

Microsoft Teams meeting

Join on your computer, mobile app or room device
Click here to join the meeting

(b)(6)

Download Teams | Join on the web

Or call in (audio only)

(b)(6)

Find a local number | Reset PIN

Learn More | Meeting options

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 13:53:48 +0000
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: new draft

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 8:52 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: new draft

RE – pg 14, (b)(5)

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 8:26 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: new draft

OK—document is linked above and also just saved if you want to drag and drop. I did not make the (b)(5) in the interest of time.

Attestation: (b)(5) (see page 5)

Please look at page 14 and (b)(5)

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 13:45:48 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: new draft

Ok, I just sent a question to our folks and Jim (b)(5)

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 8:43 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: RE: new draft

Yeah—I called Henry because I was (b)(5)

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 8:38 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: new draft

(b)(5)

Should we check with Jim on the question of i (b)(5)

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 8:26 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: new draft

OK—document is linked above and also just saved if you want to drag and drop. I did not make the (b)(5) in the interest of time.

Attestation (b)(5) (see page 5)

Please look at page 14 and (b)(5) !!

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 13:38:07 +0000
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Walke, Henry (CDC/DDPHSIS/CPR/OD)
Subject: RE: news

(b)(5)

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 8:36 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: Re: news

(b)(5)

Cate

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 7:33:34 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: news

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 8:32 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: news

https://www.cnbc.com/2022/12/28/us-new-measures-travelers-from-china.html
https://www.washingtonpost.com/world/2022/12/28/china-reopening-travel-japan-restrictions/
https://www.reuters.com/world/us-weighs-new-covid-rules-travelers-china-us-officials-say-2022-12-28/

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 19:33:07 +0000
To: Lubar, Debra (CDC/DDID/NCEZID/OD); Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR); Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Walker, Desiree (CDC/DDPHSIS/CPR/DSLR) (CTR)
Subject: RE: Notification to Big 4

Thanks. I may be able to join as well to answer questions.

From: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Sent: Wednesday, December 28, 2022 2:30 PM
To: Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR) <htv4@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walker, Desiree (CDC/DDPHSIS/CPR/DSLR) (CTR) <pge8@cdc.gov>
Subject: RE: Notification to Big 4

Thanks, sounds perfect.

From: Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR) <htv4@cdc.gov>
Sent: Wednesday, December 28, 2022 2:03 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walker, Desiree (CDC/DDPHSIS/CPR/DSLR) (CTR) <pge8@cdc.gov>
Subject: RE: Notification to Big 4

And the call will be set up for 315 today (not 3PM) and Henry will be the main speaker. Coming to your inboxes in a min.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 1:49 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR) <htv4@cdc.gov>
Subject: RE: Notification to Big 4

Adding Kris to confirm Henry is set for this

From: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Sent: Wednesday, December 28, 2022 1:48 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Notification to Big 4

Great, Henry much better than me ☺

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 1:47 PM
To: Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Notification to Big 4
Importance: Low

We just talked with Kris K. Henry will be on and can answer most questions at this point from what we know and are still working through

---

From: Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Sent: Wednesday, December 28, 2022 1:30 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Subject: Notification to Big 4

I realize things are unspeakably busy in DGMQ (b)(5) (b)(5) (b)(5) Is there, by chance, someone who can be on a 3:00 meeting to answer questions? Henry is going to try and be on and can be a spokesperson (b)(5) (b)(5) (b)(5) please let us know that too.

Thank you,

Sara
Office Phone: 404-639-0879 | Mobile Phone: 404-772-9348

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 1:17 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Brown, Tiffany J. (CDC/OD/OCS) <iji3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R.

(CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

THN looks good. Will send to Angela after OGC clearance

From: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Sent: Wednesday, December 28, 2022 1:06 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Brown, Tiffany J. (CDC/OD/OCS) <iji3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

OK…Julia/Nicky, can you let Henry know when OGC has cleared, as well?

From: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Sent: Wednesday, December 28, 2022 12:55 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Brown, Tiffany J. (CDC/OD/OCS) <iji3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: Re: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Thanks. I don't need to clear
Henry should (b)(5)
Adding @Brown, Tiffany J. (CDC/OD/OCS) for awareness as well
Thanks

From: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Sent: Wednesday, December 28, 2022 12:50:29 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Sherri, here' the THN level 2 (attached and linked) for your approval and then transmittal. OGC is reviewing as well.

From: Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Sent: Wednesday, December 28, 2022 12:44 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Nothing additional from me. Thanks for the opportunity to review.
Deb do you want to send to Sherri after your review?

Sara
Office Phone: 404-639-0879 | Mobile Phone: 404-772-9348

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 12:40 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Just a note to say that—as I'm sure you've guessed—is on a very tight timeline. Can you let us know ASAP?

Adding Henry and Lisa so they know it's moving.

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Wednesday, December 28, 2022 12:37 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon
Importance: High

Sara, Deb,

(b)(5) and will likely post this afternoon. Could you please clear this version and share with Sherri?

The content is pretty similar (b)(5)

(b)(5)

(b)(5)

OGC is reviewing the topline blurb simultaneously.

Level 2_THN_China_12.28.2022_clean.docx

Thanks,
Nicky.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 18:42:07 +0000
To: Lubar, Debra (CDC/DDID/NCEZID/OD); Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Notification to Big 4

Just talked with Kris K. They are setting up the call and I think she was going to have Henry roll over to that from the press briefing

---

From: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Sent: Wednesday, December 28, 2022 1:39 PM
To: Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: RE: Notification to Big 4

Cate, Lisa, I can cover this if you trust me to tell the story correctly. Also happy to have DGMQ tke the lead or back me up.

From: Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Sent: Wednesday, December 28, 2022 1:30 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Subject: Notification to Big 4
Importance: Low

I realize things are unspeakably busy in DGMQ (b)(5) (b)(5) (b)(5) Is there, by chance, someone who can be on a 3:00 meeting to answer questions? Henry is going to try and be on and can be a spokesperson (b)(5) (b)(5) (b)(5) please let us know that too.

Thank you,

Sara
Office Phone: 404-639-0879 | Mobile Phone: 404-772-9348

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 1:17 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Brown, Tiffany J. (CDC/OD/OCS) <jji3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia

(CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

THN looks good. Will send to Angela after OGC clearance

From: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Sent: Wednesday, December 28, 2022 1:06 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Brown, Tiffany J. (CDC/OD/OCS) <iji3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

OK…Julia/Nicky, can you let Henry know when OGC has cleared, as well?

From: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Sent: Wednesday, December 28, 2022 12:55 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Brown, Tiffany J. (CDC/OD/OCS) <iji3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: Re: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Thanks. I don't need to clear
Henry should confirm it's what was agreed upon and (b)(5)
Adding @Brown, Tiffany J. (CDC/OD/OCS) for awareness as well
Thanks

From: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Sent: Wednesday, December 28, 2022 12:50:29 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Sherri, here' the THN level 2 (attached and linked) for your approval and then transmittal. OGC is reviewing as well.

From: Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Sent: Wednesday, December 28, 2022 12:44 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Nothing additional from me. Thanks for the opportunity to review.
Deb do you want to send to Sherri after your review?

Sara
Office Phone: 404-639-0879 | Mobile Phone: 404-772-9348

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 12:40 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon

Just a note to say that—as I'm sure you've guessed—is on a very tight timeline. Can you let us know ASAP?

Adding Henry and Lisa so they know it's moving.

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Wednesday, December 28, 2022 12:37 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Vagi, Sara J. (CDC/DDPHSIS/CPR/DEO) <hgq2@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: For urgent review: China L2 THN (Close Hold) -- for likely posting this afternoon
Importance: High

Sara, Deb,

(b)(5) and will likely post this afternoon. Could you please clear this version and share with Sherri?

The content is pretty similar (b)(5)

(b)(5)

OGC is reviewing the topline blurb simultaneously.

Level 2_THN_China_12.28.2022_clean.docx

Thanks,
Nicky.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Sat, 31 Dec 2022 13:27:47 +0000
To: Susan Hopkins
Cc: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ)
Subject: Re: OFFICIAL: US and C19 - pre travel testing

You're welcome. I've cc'd Cindy on this email (forgot to add her on the last one). Here is a description of the program.

https://wwwnc.cdc.gov/travel/page/travel-genomic-surveillance

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>
Sent: Saturday, December 31, 2022 8:25:35 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: RE: OFFICIAL: US and C19 - pre travel testing

OFFICIAL

Thank you

Prof Susan Hopkins
Chief Medical Advisor,
UK Health Security Agency

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: 31 December 2022 13:25
To: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>
Subject: Re: OFFICIAL: US and C19 - pre travel testing

Hi Susan. It is anonymous. I've cc'd our lead for this program, Dr Cindy Friedman who can provide more information.

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>
Sent: Saturday, December 31, 2022 8:19:12 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: RE: OFFICIAL: US and C19 - pre travel testing

OFFICIAL

Lisa – sorry to disturb.

You mentioned pooled sampling of border entrants – is this anonymous? Is there a protocol available that you could share?

Many thanks
Susan

Prof Susan Hopkins
Chief Medical Advisor,
UK Health Security Agency

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: 30 December 2022 16:10
To: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Hughes-Baker, Laura J. (CDC/DDID/OD) <bkz2@cdc.gov>
Subject: RE: OFFICIAL: US and C19 - pre travel testing

If we could do a quick teams call that would probably be easiest. I have time before 2pm EST but tied up with other calls after that. Thank you.

From: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>
Sent: Friday, December 30, 2022 11:07 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Hughes-Baker, Laura J. (CDC/DDID/OD) <bkz2@cdc.gov>
Subject: Re: OFFICIAL: US and C19 - pre travel testing

Today would be great if you can spare 10 mins.

On my mobile (b)(6) or can set up teams/ zoom.

Sent from Outlook for iOS

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Friday, December 30, 2022 3:47:18 PM
To: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Hughes-Baker, Laura J. (CDC/DDID/OD) <bkz2@cdc.gov>
Subject: RE: OFFICIAL: US and C19 - pre travel testing

Hi Susan,
Probably easier to talk through via phone. Happy to have a short call today or perhaps Monday if that would work for you.

Lisa

From: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>
Sent: Friday, December 30, 2022 10:16 AM
To: Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Hughes-Baker, Laura J. (CDC/DDID/OD) <bkz2@cdc.gov>
Subject: RE: OFFICIAL: US and C19 - pre travel testing

Thanks Jay – and Hi Lisa

(b)(5)

Prof Susan Hopkins
Chief Medical Advisor,
UK Health Security Agency

From: Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>
Sent: 30 December 2022 15:13
To: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>; Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Hughes-Baker, Laura J. (CDC/DDID/OD) <bkz2@cdc.gov>
Subject: RE: OFFICIAL: US and C19 - pre travel testing

Hello, Susan—We just spent some time with our Canadian colleagues discussing this very topic. There are some more detailed documents, such as an FAQ list, that are in development, and that we can share when finalized. I am looping in Dr. Lisa Rotz from our Division of Global Migration and Quarantine to let her know of the interest from the UK and to provide alert her to your interest. If a call to discuss is needed, we could schedule that or we could have this as an additional topic for our regularly scheduled call with Israel on Jan 6.
Best wishes for 2023!
Jay

Jay C. Butler, MD, FAAP, MACP, FIDSA
Deputy Director for Infectious Diseases
Centers for Disease Control and Prevention
Cell: 404-432-2275

From: Susan Hopkins <Susan.Hopkins@ukhsa.gov.uk>
Sent: Friday, December 30, 2022 8:02 AM
To: Brooks, John T. (CDC/DDID/NCHHSTP/DHP) <zud4@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>
Subject: OFFICIAL: US and C19 - pre travel testing

OFFICIAL

John and Jay –

I hope you have had a few days down time over the holidays.

We are getting asked questions related to your pre-travel testing recommendations from China. (b)(5)

(b)(5)

Susan.

UK Health Security Agency

Prof Susan Hopkins
Chief Medical Advisor
Clinical and Public Health Group
UK Health Security Agency
Susan.hopkins@ukhsa.gov.uk
Tel: 07976 539735
www.gov.uk/ukhsa Follow us on Twitter @UKHSA

Professor of Infectious Diseases and Health Security,
UCL

Consultant in Infectious Diseases & Microbiology,
Royal Free London

HANDLING INSTRUCTIONS
If this email is protectively marked at OFFICIAL–SENSITIVE it should be shared only on a "need to know" basis and not made available to others. If you retain a paper copy it must be stored securely, and destroyed using an approved shredder when no longer required. Similarly, electronic copies should be stored securely and not made available to others without authority from the originator. If you are not clear on handling, please refer to the UKHSA Security Officer for advice.

****
******
The information contained in the Email and any attachments is confidential and intended solely and for the attention and use of the named addressee(s). It may not be disclosed to any other person without the express authority of the UKHSA, or the intended recipient or both. If you are not the intended recipient, you must not disclose, copy, distribute or retain this message or any part of it. This footnote also confirms that this Email has been swept for computer viruses by Exchange Online Protection, but please re-sweep any attachments before opening or saving. UK Health Security Agency - (https://www.gov.uk/government/organisations/uk-health-security-agency)
****
******
****
******
The information contained in the Email and any attachments is confidential and intended solely and for the attention and use of the named addressee(s). It may not be disclosed to any other person without the express authority of the UKHSA, or the intended recipient or both. If you are not the intended recipient, you must not disclose, copy, distribute or retain this message or any part of it. This footnote also confirms that this Email has been swept for computer viruses by Exchange Online Protection, but please re-sweep any attachments before opening or saving. UK Health Security Agency - (https://www.gov.uk/government/organisations/uk-health-security-agency)

****
****

****
****
The information contained in the Email and any attachments is confidential and intended solely and for the attention and use of the named addressee(s). It may not be disclosed to any other person without the express authority of the UKHSA, or the intended recipient or both. If you are not the intended recipient, you must not disclose, copy, distribute or retain this message or any part of it. This footnote also confirms that this Email has been swept for computer viruses by Exchange Online Protection, but please re-sweep any attachments before opening or saving. UK Health Security Agency -(https://www.gov.uk/government/organisations/uk-health-security-agency)
****
****

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 21:54:52 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Order Press Release

Got it, thx

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 4:37 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: Order Press Release

That is usually what happens it is on the China page but sometimes the other links are delayed

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 4:36 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: Order Press Release

I think the weird thing is that it's not linked on the main THN page yet, but it will be… soon, right Cate?

https://wwwnc.cdc.gov/travel/notices

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 4:35 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: Order Press Release

I went through CDC.gov on our external website to find and was able to open the link.

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 4:32 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Order Press Release

Live link- https://wwwnc.cdc.gov/travel/notices/alert/covid-19-china-hong-kong-macau

I just checked wasn't live yet

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 4:31 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: FW: Order Press Release

Cindy is THN live, is there a link? NSC asking

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wednesday, December 28, 2022 3:31 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

Shared and flagged posted at 330

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:15 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ)

<wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

Julia and Henry, can you flag up that it will be posted by 3:30?

Cindy, can you share the link when it is live?

Cate

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:14 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

HHS is an FYI so can we post it --?

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:13 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: Order Press Release

It can go up as soon as it is ready to go.

Same with the blurb/box for the COVID-19 travel sites. As soon as ready.

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Wednesday, December 28, 2022 3:11 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: Order Press Release

Thanks, Cate.

If the press release is posted, can we post the THN? How long do we need to wait after it goes up to HHS?

Nicky.

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:08 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: Order Press Release

Hi all – not sure who all to send this to, so sharing so you can send it yourself ☺

Thank you to Henry, who did a great job on the press briefing!

CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People's Republic of China | CDC Online Newsroom | CDC

Cate

Caitlin Shockey, JD

Associate Director for Communication
Division of Global Migration and Quarantine
Centers for Disease Control and Prevention
404.831.0025
cshockey@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 21:34:54 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Walke, Henry (CDC/DDPHSIS/CPR/OD)
Subject: RE: Order Press Release

Yes

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 4:34 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: RE: Order Press Release

I think it's live, right?
https://wwwnc.cdc.gov/travel/notices/alert/covid-19-china-hong-kong-macau

---

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 4:32 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Order Press Release

Live link- https://wwwnc.cdc.gov/travel/notices/alert/covid-19-china-hong-kong-macau

I just checked wasn't live yet

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 4:31 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: FW: Order Press Release

Cindy is THN live, is there a link? NSC asking

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wednesday, December 28, 2022 3:31 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

Shared and flagged posted at 330

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:15 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

Julia and Henry, can you flag up that it will be posted by 3:30?

Cindy, can you share the link when it is live?

Cate

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:14 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

HHS is an FYI so can we post it --?

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:13 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: Order Press Release

It can go up as soon as it is ready to go.

Same with the blurb/box for the COVID-19 travel sites. As soon as ready.

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Wednesday, December 28, 2022 3:11 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: Order Press Release

Thanks, Cate.

If the press release is posted, can we post the THN? How long do we need to wait after it goes up to HHS?

Nicky.

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:08 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: Order Press Release

Hi all – not sure who all to send this to, so sharing so you can send it yourself 😊

Thank you to Henry, who did a great job on the press briefing!

CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People's Republic of China | CDC Online Newsroom | CDC

Cate

Caitlin Shockey, JD
Associate Director for Communication
Division of Global Migration and Quarantine
Centers for Disease Control and Prevention
404.831.0025
cshockey@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 21:33:30 +0000
To: Walke, Henry (CDC/DDPHSIS/CPR/OD); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ)
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Order Press Release

COVID-19 in China, Hong Kong, and Macau - Alert - Level 2, Practice Enhanced Precautions - Travel Health Notices | Travelers' Health | CDC

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 4:31 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: FW: Order Press Release

Cindy is THN live, is there a link? NSC asking

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wednesday, December 28, 2022 3:31 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

Shared and flagged posted at 330

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:15 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

Julia and Henry, can you flag up that it will be posted by 3:30?

Cindy, can you share the link when it is live?

Cate

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:14 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Order Press Release

HHS is an FYI so can we post it --?

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:13 PM
To: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: Order Press Release

It can go up as soon as it is ready to go.

Same with the blurb/box for the COVID-19 travel sites. As soon as ready.

From: Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Sent: Wednesday, December 28, 2022 3:11 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Subject: RE: Order Press Release

Thanks, Cate.

If the press release is posted, can we post the THN? How long do we need to wait after it goes up to HHS?

Nicky.

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Wednesday, December 28, 2022 3:08 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: Order Press Release

Hi all – not sure who all to send this to, so sharing so you can send it yourself 😊

Thank you to Henry, who did a great job on the press briefing!

CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People's Republic of China | CDC Online Newsroom | CDC

Cate

Caitlin Shockey, JD
Associate Director for Communication
Division of Global Migration and Quarantine
Centers for Disease Control and Prevention
404.831.0025
cshockey@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Thu, 29 Dec 2022 21:15:26 +0000
To: Weatherdon, Neil (PHAC/ASPC); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Cc: Brown, Jennifer (PHAC/ASPC)
Subject: RE: Pre-departure Test for China

Got it

From: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Sent: Thursday, December 29, 2022 4:14 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Thanks Lisa – just sent an invitation.

Neil

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: 2022-12-29 4:04 PM
To: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

I can talk right now if you can. Unavailable after 5pm.

From: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Sent: Thursday, December 29, 2022 4:01 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Sorry Lisa – would you happen to have any time this afternoon? We are under quite a bit of pressure to have answers to some questions regarding the announced measures

Many thanks,

Neil

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: 2022-12-29 3:16 PM
To: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>; Charles, Julia

(CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Hi Neil,
Julia will most likely be tied up tomorrow so perhaps I can chat with you all.

Lisa

From: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Sent: Thursday, December 29, 2022 3:14 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Hi Julia,

Would you happen to have a bit of time tomorrow morning to discuss the roll-out of pre-departure testing?

Many thanks,

Neil

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: 2022-12-28 3:06 PM
To: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People's Republic of China | CDC Online Newsroom | CDC
Sharing this… happy to talk.

From: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Sent: Wednesday, December 28, 2022 3:04 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Hi Julia – I tried that number and it didn't go through. Is there another way to connect? Unfortunately, I need to jump into meetings now.

Thanks,

Neil

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: 2022-12-28 2:55 PM
To: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Hi Neil,

I really apologize for not being able to share this earlier. We are posting an announcement at 3pm.

Can you give me a call? (b)(6)

From: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Sent: Wednesday, December 28, 2022 2:52 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Hi Julia – I have a number of meetings starting in about 10 mins. Would it be possible to seek clarity on the following: (b)(5)
(b)(5)
(b)(5) There are a lot of different messages being reported.

Many thanks,

Neil

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: 2022-12-28 11:46 AM
To: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

Thanks—we may have to wait until a little later in the day. Please stand by. We appreciate your patience!!

From: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Sent: Wednesday, December 28, 2022 11:42 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>

Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Brown, Jennifer (PHAC/ASPC) <jennifer.brown@phac-aspc.gc.ca>
Subject: RE: Pre-departure Test for China

For sure – I am available at 12:30pm. I will ask one member of the team to sit in.

Many thanks,

Neil

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: 2022-12-28 11:35 AM
To: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: RE: Pre-departure Test for China

Just a follow up to request we keep the call very small and this information close hold.

From: Weatherdon, Neil (PHAC/ASPC) <Neil.Weatherdon@phac-aspc.gc.ca>
Sent: Wednesday, December 28, 2022 11:29 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Pre-departure Test for China

Good morning Julia,

I hope you had a nice Christmas.

We have been advised that the US will be announcing, as early as today:

- A new PCR testing requirement 48 hours before flight, for all travelers en route to US from China, HK and Macau - to take effect Jan 3.
- A requirement for travelers who have been in the PRC within the prior ten days, traveling to the US from anywhere, to present a negative PCR test before flight boarding.

Are you able to 1) confirm that this will be announced, as well as timing; (b)(5)

(b)(5)

Many thanks,

Neil

Neil Weatherdon
Associate Director General | Directeur général associé
Centre for Border and Travel Health | Centre pour la santé aux frontières et aux voyages
Public Health Agency of Canada | Agence de la santé publique du Canada
neil.weatherdon@phac-aspc.gc.ca / Tel: 613-608-9238

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Thu, 29 Dec 2022 16:27:11 +0000
To: Myers, Rebecca (CDC/DDID/NCEZID/DGMQ); Stolp, Amber (CDC/DDID/NCEZID/DGMQ); Brown, Clive (CDC/DDID/NCEZID/DGMQ); Roohi, Shahrokh (CDC/DDID/NCEZID/DGMQ); Hansen, Sabrina (CDC/DDID/NCEZID/DGMQ)
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Public TPS

(b)(5)

From: Myers, Rebecca (CDC/DDID/NCEZID/DGMQ) <asx1@cdc.gov>
Sent: Thursday, December 29, 2022 11:24 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Brown, Clive (CDC/DDID/NCEZID/DGMQ) <cmb8@cdc.gov>; Roohi, Shahrokh (CDC/DDID/NCEZID/DGMQ) <snr2@cdc.gov>; Hansen, Sabrina (CDC/DDID/NCEZID/DGMQ) <YPJ8@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Subject: RE: Public TPS

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Thursday, December 29, 2022 11:08 AM
To: Stolp, Amber (CDC/DDID/NCEZID/DGMQ) <wmg9@cdc.gov>; Brown, Clive (CDC/DDID/NCEZID/DGMQ) <cmb8@cdc.gov>; Myers, Rebecca (CDC/DDID/NCEZID/DGMQ) <asx1@cdc.gov>; Roohi, Shahrokh (CDC/DDID/NCEZID/DGMQ) <snr2@cdc.gov>; Hansen, Sabrina (CDC/DDID/NCEZID/DGMQ) <YPJ8@cdc.gov>
Cc: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Cohen, Nicole (Nicky) (CDC/DDID/NCEZID/DGMQ) <hei1@cdc.gov>
Subject: Public TPS

Here were the public TPs that I referred to on our call.

From: Svenstrup, Mary V. EOP/NSC (b)(6)
Sent: Wednesday, December 28, 2022 8:52 PM
To: Grant Harris (Federal) <Grant.Harris@trade.gov>; Segal-Knowles, Christina M. EOP/NSC (b)(6) Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Carter, Hillary H. EOP/NSC (b)(6) Petsonk, Annie (OST) <carol.petsonk@dot.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Panjabi, Raj R.

EOP/NSC (b)(6) Knight, Nancy W. EOP/NSC (b)(6)
Subject: RE: Supply Chains / China

Grant, please see attached for the latest public talking points. Please let us know if you have any questions.

From: Grant Harris (Federal) <Grant.Harris@trade.gov>
Sent: Wednesday, December 28, 2022 5:01 PM
To: Segal-Knowles, Christina M. EOP/NSC (b)(6) Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Carter, Hillary H. EOP/NSC <Hillary.H.Carter@nsc.eop.gov>; Petsonk, Annie (OST) <carol.petsonk@dot.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Panjabi, Raj R. EOP/NSC <Rajesh.R.Panjabi@nsc.eop.gov>; Knight, Nancy W. EOP/NSC (b)(6) Svenstrup, Mary V. EOP/NSC (b)(6)
Subject: Re: Supply Chains / China

Hi all,
Are there TPs for USG use in explaining the order that we can use to answer questions from industry?
Thank you.
Grant

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 13:52:49 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: QAs for the Order

I poured coffee in my mug – 4 times as of right now 😊

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 8:51 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

I poured milk that was meant for coffee into my glass of ice!!!

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 8:47 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

I read 9 anyway even though it said 845 😊 I poured my cream into a glass of water instead of my coffee this AM – don't tell anyone 😊

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 8:46 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

9! Where did I get 845???

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 8:44 AM

To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: Re: QAs for the Order

Yes

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 8:43:13 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

Cindy—just sent you an invite for an update with CGH at 845. Can you join?

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 8:27 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: QAs for the Order

Yes it is ready for clx. Just adding the pre D language up top.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 8:19:28 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: QAs for the Order

As per Julia, (b)(5) But we should get the wording drafted and ready.

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 9:24 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: QAs for the Order

Thanks. We can send to clearance tomorrow.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 8:57:45 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ)

<yyb1@cdc.gov>
Subject: Fwd: QAs for the Order

FYI

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Sent: Monday, December 26, 2022 8:56:48 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Jackson, Brendan R. (CDC/DDID/NCEZID/DFWED) <iyn0@cdc.gov>
Cc: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Subject: RE: QAs for the Order

Update: I was told (b)(5)
(b)(5)

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Monday, December 26, 2022 8:04 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Jackson, Brendan R. (CDC/DDID/NCEZID/DFWED) <iyn0@cdc.gov>
Cc: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Subject: QAs for the Order

Hi team,

While waiting for the readout from the DC meeting, trying to get ahead of the Pre-Travel Testing Order QA document for HHS and the WH. QA_Pre-Travel Testing Requirement_PRC_Dec 26.docx

90% of the answers are from cleared QA from the previous global testing order. Please let me know if there are additional Qs that you think we need.

The Travel-Based Genomic Sequencing Program already has a whole website. Traveler-Based Genomic Surveillance for Early Detection of New SARS-CoV-2 Variants | Travelers' Health | CDC

Cate

Caitlin Shockey, JD
Associate Director for Communication
Division of Global Migration and Quarantine
Centers for Disease Control and Prevention
404.831.0025
cshockey@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 13:44:08 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: QAs for the Order

I have the update on my calendar as 0900? Did it change?

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 8:43 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

Cindy—just sent you an invite for an update with CGH at 845. Can you join?

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 8:27 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: QAs for the Order

Yes it is ready for clx. Just adding the pre D language up top.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 8:19:28 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: QAs for the Order

As per Julia, (b)(5) But we should get the wording drafted and ready.

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 9:24 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: QAs for the Order

Thanks. We can send to clearance tomorrow.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 8:57:45 PM

To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Fwd: QAs for the Order

FYI

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Sent: Monday, December 26, 2022 8:56:48 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Jackson, Brendan R. (CDC/DDID/NCEZID/DFWED) <iyn0@cdc.gov>
Cc: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Subject: RE: QAs for the Order

Update: I was told C (b)(5)
(b)(5)

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Monday, December 26, 2022 8:04 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Jackson, Brendan R. (CDC/DDID/NCEZID/DFWED) <iyn0@cdc.gov>
Cc: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Subject: QAs for the Order

Hi team,

While waiting for the readout from the DC meeting, trying to get ahead of the Pre-Travel Testing Order QA document for HHS and the WH. QA_Pre-Travel Testing Requirement_PRC_Dec 26.docx

90% of the answers are from cleared QA from the previous global testing order. Please let me know if there are additional Qs that you think we need.

The Travel-Based Genomic Sequencing Program already has a whole website. Traveler-Based Genomic Surveillance for Early Detection of New SARS-CoV-2 Variants | Travelers' Health | CDC

Cate

Caitlin Shockey, JD
Associate Director for Communication
Division of Global Migration and Quarantine
Centers for Disease Control and Prevention
404.831.0025
cshockey@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 13:50:43 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: QAs for the Order

#secretsafewithus

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 8:47 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

I read 9 anyway even though it said 845 😊 I poured my cream into a glass of water instead of my coffee this AM – don't tell anyone 😊

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 8:46 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

9! Where did I get 845???

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 8:44 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: Re: QAs for the Order

Yes

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 8:43:13 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa

(CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: RE: QAs for the Order

Cindy—just sent you an invite for an update with CGH at 845. Can you join?

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 8:27 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: QAs for the Order

Yes it is ready for clx. Just adding the pre D language up top.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 8:19:28 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: QAs for the Order

As per Julia, (b)(5) But we should get the wording drafted and ready.

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Monday, December 26, 2022 9:24 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: QAs for the Order

Thanks. We can send to clearance tomorrow.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Monday, December 26, 2022 8:57:45 PM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Fwd: QAs for the Order

FYI

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Sent: Monday, December 26, 2022 8:56:48 PM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Jackson, Brendan R. (CDC/DDID/NCEZID/DFWED) <iyn0@cdc.gov>
Cc: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Subject: RE: QAs for the Order

Update: I was told (b)(5)
(b)(5)

From: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Sent: Monday, December 26, 2022 8:04 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Jackson, Brendan R. (CDC/DDID/NCEZID/DFWED) <iyn0@cdc.gov>
Cc: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Subject: QAs for the Order

Hi team,

While waiting for the readout from the DC meeting, trying to get ahead of the Pre-Travel Testing Order QA document for HHS and the WH. QA_Pre-Travel Testing Requirement_PRC_Dec 26.docx

90% of the answers are from cleared QA from the previous global testing order. Please let me know if there are additional Qs that you think we need.

The Travel-Based Genomic Sequencing Program already has a whole website. Traveler-Based Genomic Surveillance for Early Detection of New SARS-CoV-2 Variants | Travelers' Health | CDC

Cate

Caitlin Shockey, JD
Associate Director for Communication
Division of Global Migration and Quarantine
Centers for Disease Control and Prevention
404.831.0025
cshockey@cdc.gov

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 21:43:09 +0000
To: Nordlund, Kristen (CDC/OD/OADC)
Cc: Griffis, Kevin (CDC/OD/OADC); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Quick question from today's briefing

That's what Nahid said from the WH. That's right. Data from here

https://gisaid.org/submission-tracker-global/

From: Nordlund, Kristen (CDC/OD/OADC) <hok4@cdc.gov>
Sent: Wednesday, December 28, 2022 4:30 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: FW: Quick question from today's briefing

Hi Henry,

Below is a request from the South China Morning Post looking to clarify what you said. Is the below correct?

Thanks,
Kristen

From: Jacob Fromer <jacob.fromer@scmp.com>
Sent: Wednesday, December 28, 2022 4:23 PM
To: Nordlund, Kristen (CDC/OD/OADC) <hok4@cdc.gov>
Subject: Quick question from today's briefing

Hi Kristen,
I have a quick question from today's China briefing.
I was on the call but want to confirm that I got these numbers right from what the officials said.

"As of this morning, the percentage of reported cases that are sequenced and shared by the PRC is .036 per cent, compared to about 4.4 per cent of the US cases," one of the officials said.

Is this correct?

Thanks so much.
Jake
518-469-4690
South China Morning Post

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 22:17:24 +0000
To: Walke, Henry (CDC/DDPHSIS/CPR/OD); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Berger, Sherri (CDC/OD/OCS)
Subject: RE: recent China call

(b)(5) so should they join the 5:30 call?

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Tuesday, December 27, 2022 5:07 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: RE: recent China call

Lots of discussion back and forth. (b)(5)

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 5:04 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: RE: recent China call

Thanks Henry. Questions on bullet 2 that can hopefully clear up on the call at 5:30 in order to figure out h (b)(5)

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Tuesday, December 27, 2022 4:56 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: recent China call

(b)(5)

Henry Walke, MD, MPH (he/him)
Director, Center for Preparedness and Response (CPR)
CDC, HHS
+1-404-639-3582 (office)
+1-404-452-9624 (mobile)
hwalke@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 22:18:30 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: recent China call

Yes, I'm not inviting anyone

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 5:06 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: Re: recent China call

Just a note that call at 530 only for small group!

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 5:03:36 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: RE: recent China call

Thanks Henry. Questions on bullet 2 that can hopefully clear up on the call at 5:30 in order to figure out (b)(5)

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Tuesday, December 27, 2022 4:56 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: recent China call

(b)(5)

Henry Walke, MD, MPH (he/him)
Director, Center for Preparedness and Response (CPR)
CDC, HHS
+1-404-639-3582 (office)
+1-404-452-9624 (mobile)
hwalke@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 22:14:39 +0000
To: Berger, Sherri (CDC/OD/OCS); Walke, Henry (CDC/DDPHSIS/CPR/OD); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: recent China call

Thanks.

From: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Sent: Tuesday, December 27, 2022 5:10 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: recent China call

Worst case scenario, (b)(5)
(b)(5) Or something like that. Thanks

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 5:03:36 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: RE: recent China call

Thanks Henry. Questions on bullet 2 that can hopefully clear up on the call at 5:30 in order to figure out (b)(5)

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Tuesday, December 27, 2022 4:56 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Subject: recent China call

(b)(5)

Henry Walke, MD, MPH (he/him)
Director, Center for Preparedness and Response (CPR)
CDC, HHS
+1-404-639-3582 (office)
+1-404-452-9624 (mobile)
hwalke@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Thu, 29 Dec 2022 13:59:56 +0000
To: Weakland, Aliki P. (CDC/DDID/NCEZID/DPEI)
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD); Byrkit, Ramona (CDC/DDPHSIS/CPR/DSLR); Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Request to join upcoming partner call re: Testing requirement for air passengers (China)

I can join. Thanks.

From: Weakland, Aliki P. (CDC/DDID/NCEZID/DPEI) <agp4@cdc.gov>
Sent: Thursday, December 29, 2022 8:58 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Byrkit, Ramona (CDC/DDPHSIS/CPR/DSLR) <qpa1@cdc.gov>; Kosmos, Christine (CDC/DDPHSIS/CPR/DSLR) <htv4@cdc.gov>
Subject: Request to join upcoming partner call re: Testing requirement for air passengers (China)
Importance: High

Good morning, Lisa.

I understand that there is a request for you to join the upcoming **Tuesday morning Response Core Partner Call on 1/3 (7:45 - 8:30 AM ET)**, to review the information shared yesterday re: Negative COVID-19 Test Requirement from Air Passengers Entering the United States from China, provide any updates and answer any questions from partners. AS a reminder, this call is small and with leadership from the Core-5 PH partner organizations.

Currently there is one other COVID topic scheduled for the 1/3 call and there may be an mpox topic on the agenda as well. **You would likely have 10-15 minutes all in for sharing any information and fielding questions.**

Please let me know if you (or a member of your team) is available for the call.

Many thanks,
Aliki

Aliki Pappas Weakland, MPH MSW (she/her/hers)
Public Health Partnerships
-Domestic Preparedness and Response Task Force, Uganda Sudan Virus Outbreak Response
-State, Tribal, Local and Territorial Support Task Force, COVID-19 Response
Centers for Disease Control and Prevention (CDC)
e: agp4@cdc.gov
m: 678.488.7327

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Thu, 29 Dec 2022 18:26:30 +0000
To: Griffis, Kevin (CDC/OD/OADC); Berger, Sherri (CDC/OD/OCS)
Subject: Re: request

330 to 5 pm available

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Thursday, December 29, 2022 11:00:40 AM
To: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: Re: request

1130 to noon, 230-430

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Sent: Thursday, December 29, 2022 10:56:06 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: Re: request

Are there good windows for you today?

Get Outlook for iOS
From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Thursday, December 29, 2022 10:54:53 AM
To: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: Re: request

Sure, I can talk with her

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Griffis, Kevin (CDC/OD/OADC) <tvw8@cdc.gov>
Sent: Thursday, December 29, 2022 10:45:12 AM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: Re: request

We got a similar request from Katelyn Jetelina, who said she is trying to understand the math behind the order and how it will decrease the likelihood of transmission. Any chance you would have time to talk with her, Henry?

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Fri, 30 Dec 2022 13:58:10 +0000
To: Tress, Deborah W. (CDC/OCOO/OGC); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Cc: Misrahi, James J. (CDC/OCOO/OGC); Walters, Justine (CDC/OCOO/OGC); Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ)
Subject: Re: Surveillance issues

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Tress, Deborah W. (CDC/OCOO/OGC) <dew3@cdc.gov>
Sent: Friday, December 30, 2022 8:57:21 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>; Walters, Justine (CDC/OCOO/OGC) <uee0@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Surveillance issues

Thanks Julia!
We are looking at the (b)(5)
(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Friday, December 30, 2022 8:53 AM
To: Tress, Deborah W. (CDC/OCOO/OGC) <dew3@cdc.gov>
Cc: Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>; Walters, Justine (CDC/OCOO/OGC) <uee0@cdc.gov>; Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Subject: RE: Surveillance issues

Wanted to flag this for our OGC friends… increased press yesterday on WW surveillance

https://www.reuters.com/business/healthcare-pharmaceuticals/us-considers-airline-wastewater-testing-covid-surges-china-2022-12-30

https://www.theguardian.com/world/2022/dec/30/china-covid-experts-estimate-9000-deaths-a-day-as-us-says-it-may-sample-wastewater-from-planes

The CDC press statement says "CDC is exploring all options to help slow the introduction of new variants into the United States, from China and other countries. Previous COVID-19 wastewater surveillance has shown to be a valuable tool and airplane wastewater surveillance could potentially be an option."

We may get asked about it on the airline call today (5pm, I think?) (b)(5) (b)(5) … in all of your spare time. 😊

From: Tress, Deborah W. (CDC/OCOO/OGC) <dew3@cdc.gov>
Sent: Tuesday, December 27, 2022 11:40 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>; Walters, Justine (CDC/OCOO/OGC) <uee0@cdc.gov>
Subject: Surveillance issues

Hi Julia,
We have a couple (b)(5)

(b)(5)

(b)(5) Just want to get our research rolling.
Thanks!

Deborah Weimer Tress
CDC Legal Advisor
HHS Office of the General Counsel
Public Health Division, CDC/ATSDR Branch
(404) 639-7206
(678) 462-0226
dew3@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 15:19:27 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Cc: Ruskey, Ian (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Taiwan flights

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Tuesday, December 27, 2022 10:13 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Ruskey, Ian (CDC/DDID/NCEZID/DGMQ) <klv5@cdc.gov>
Subject: Taiwan flights

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 20:44:45 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Thanks for doing the STLT call Henry

(b)(6)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 3:42 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Henry, so appreciate you holding hands with us as we all jump! (b)(6)

(b)(6)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 3:36 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

They are pretty good. I didn't raise them though, they were born that way 😊

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 3:34 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Happy to be in the mix, your team is stellar

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 3:34 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Good. Glad wasn't too bad. Thanks again for all your support during all of this funstuff…

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 3:33 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>

Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Went fine, (b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 3:31 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Thanks for doing the STLT call Henry

Appreciate it. Wasn't sure If I'd be able to be on or not. How did the press call go. The airline assoc call went well. (b)(5) 

Lisa D. Rotz, MD, FIDSA
Acting Director
Division of Global Migration and Quarantine
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Email: LRotz@cdc.gov
Office: 404-639-4376
Mobile: 404-683-3832

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 20:44:34 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Walke, Henry (CDC/DDPHSIS/CPR/OD)
Subject: RE: Thanks for doing the STLT call Henry

Looks like a fun crew! Ah to be young and traveling internationally again (or just to be traveling internationally again……)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 3:42 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Henry, so appreciate you holding hands with us as we all jump! (b)(6)

(b)(6)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 3:36 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

They are pretty good. I didn't raise them though, they were born that way ☺

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 3:34 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Happy to be in the mix, your team is stellar

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 3:34 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Good. Glad wasn't too bad. Thanks again for all your support during all of this funstuff…

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 3:33 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thanks for doing the STLT call Henry

Went fine, (b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 3:31 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Thanks for doing the STLT call Henry

Appreciate it. Wasn't sure If I'd be able to be on or not. How did the press call go. The airline assoc call went well. (b)(5) 

Lisa D. Rotz, MD, FIDSA
Acting Director
Division of Global Migration and Quarantine
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Email: LRotz@cdc.gov
Office: 404-639-4376
Mobile: 404-683-3832

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 13:05:59 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: THN from the archives

Ok thanks!

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 8:03 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: Re: THN from the archives

Pretty much. I seem to recall (b)(5)

(b)(5)

C

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 7:59:46 AM
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: THN from the archives

Yes, thank you. So from March to Nov of 2020 we had a global level 3, right?

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Wednesday, December 28, 2022 7:22 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: THN from the archives

Morning,
Is this what you need? Happy to explain anything as needed. This is the history of the COVID THN system – from the start of the 4 tier risk assessment before that from March to Nov we had a Global Level 3 (highest)

On **November 21, 2020,** CDC adapted its 3-level notice system to a **4-level system** for COVID-19 and updated criteria used to determine THN levels. The system was updated to align with the same incidence rate or case count thresholds adopted by recognized public health organizations and shares a common 4-level structure with the U.S. Department of State's Travel Advisory system. https://web.archive.org/web/20220405090753/https://www.cdc.gov/coronavirus/2019-ncov/travelers/how-level-is-determined.html

Updates as of January 29, 2021:

This page was changed to include updated secondary criteria used to determine Travel Health Notice levels.
https://web.archive.org/web/20210131141749/https://www.cdc.gov/coronavirus/2019-ncov/travelers/how-level-is-determined.html

Updates as of February 23, 2021:
The thresholds used to evaluate secondary criteria were included on this page.
https://web.archive.org/web/20210429192541/https://www.cdc.gov/coronavirus/2019-ncov/travelers/how-level-is-determined.html

Updates as of April 28, 2021:
The page was updated to include how vaccination coverage and vaccine performance information for destinations is considered when evaluating travel health notice levels.

https://web.archive.org/web/20210408151424/https://www.cdc.gov/coronavirus/2019-ncov/travelers/how-level-is-determined.html

Updates as of June 7, 2021:
Primary and secondary criteria used to determine Travel Health Notice (THN) levels were updated to better differentiate countries with severe outbreak situations from countries with sustained, but controlled, COVID-19 spread.

This update gives specific travel advice for vaccinated and unvaccinated people according to the THN level, ensuring THN levels reflect the current global situation and are aligned with guidance for international travel.

https://web.archive.org/web/20210625104705/https://www.cdc.gov/coronavirus/2019-ncov/travelers/how-level-is-determined.html

On **April 18, 2022,** CDC updated its COVID-19 THN system. Level 4 will no longer be based on COVID-19 incidence or case count alone. It will be reserved for special circumstances, such as rapidly escalating case trajectory or extremely high case counts, emergence of a new variant of concern, and healthcare infrastructure collapse. Levels 3, 2, and 1 will still be primarily determined by 28-day incidence or case counts as outlined below.
https://web.archive.org/web/20220531082123/https://www.cdc.gov/coronavirus/2019-ncov/travelers/how-level-is-determined.html

On **On Oct 3, 2022**
CDC Removed it's country-specific COVID-19 Travel Health Notices (THNs) and began relying on existing COVID-19 International Travel advice page that was updated in line with CDC's recent guidance for the current phase of the pandemic. Incorporated COVID-19 notifications into standard THN processes and recommendations, similar to all other travel-associated diseases. Post country-specific THNs for COVID-19 only if there is a new variant of concern or other developments that warrant alerting travelers.

Cindy

Cindy R. Friedman, MD

Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Mon, 26 Dec 2022 20:29:52 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Walensky, Rochelle (CDC/OD)
Cc: Berger, Sherri (CDC/OD/OCS)
Subject: RE: THN info

State levels



From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Monday, December 26, 2022 3:26 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>
Cc: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Subject: THN info

Our THN levels:
Warning Level 3 (Red): **Avoid all non-essential travel** to this destination. The outbreak is of high risk to travelers and (b)(5)
(b)(5)
Level 2: Alert
Alert Level 2 (Yellow): **Practice enhanced precautions** for this destination. The Travel Health Notice describes additional precautions added, or defines a specific at-risk population.
Level 1: Watch
Watch Level 1 (Green): **Practice usual precautions** for this destination, as described in the Travel Health Notice and/or on the destination page. This includes being up-to-date on all recommended vaccines and practicing appropriate mosquito avoidance.

State is at 3 out of 4 for China, with reference to COVID:
https://travel.state.gov/content/travel/en/traveladvisories/traveladvisories/china-travel-advisory.html

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 12:08:03 +0000
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Thoughts on wording and reasoning below

Can we have a call, just talked with director. 404 452 9624 or teams

---

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 7:02 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

Not sure. Are we (b)(5)

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 6:48 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 9:31 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tuesday, December 27, 2022 9:13 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>

Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: Thoughts on wording and reasoning below

Julia,
Playing with the wording (b)(5)

(b)(5)

Repasting the calculations from before;

All,

In regards to interpreting this table, I spoke with Chris M. (b)(5)

(b)(5)

(b)(5)

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 12:28:25 +0000
To: Walke, Henry (CDC/DDPHSIS/CPR/OD); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Thoughts on wording and reasoning below

Sendiung teams invite so all can connect

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 7:28 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

Ok, can you call me 404 452 9624

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 7:27 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

I calculated it from the data on their table. I can s (b)(5)
(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 7:25 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

Thanks, I think (b)(5)
(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 7:21 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

Here is a further breakdown (b)(5)

(b)(5)

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 7:18 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 7:02 AM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

Not sure. Are we (b)(5)

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 6:48 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ)

<yyb1@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Tuesday, December 27, 2022 9:31 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: Thoughts on wording and reasoning below

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tuesday, December 27, 2022 9:13 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: Thoughts on wording and reasoning below

Julia,
Playing with the wording (b)(5)

(b)(5)



Repasting the calculations from before;

All,
In regards to interpreting this table, I spoke with Chris M. (b)(5)



(b)(5)

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Wed, 28 Dec 2022 18:06:32 +0000
To: Magrino, Christopher
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Misrahi, James J. (CDC/OCOO/OGC)
Subject: RE: total US bound travel volume from the 3 airports

Thanks.

From: Magrino, Christopher <Christopher.Magrino@HQ.DHS.GOV>
Sent: Wednesday, December 28, 2022 1:05 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Misrahi, James J. (CDC/OCOO/OGC) <zmr0@cdc.gov>
Subject: RE: total US bound travel volume from the 3 airports

Not yet. I will check on it.

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 1:02 PM
To: Magrino, Christopher <Christopher.Magrino@HQ.DHS.GOV>
Cc: Charles, Julia <yyb1@cdc.gov>; zmr0 <zmr0@cdc.gov>
Subject: total US bound travel volume from the 3 airports

Chris,
Were you able to (b)(5)

(b)(5)

L

Lisa D. Rotz, MD, FIDSA
Acting Director
Division of Global Migration and Quarantine
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Email: LRotz@cdc.gov
Office: 404-639-4376
Mobile: 404-683-3832

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Tue, 27 Dec 2022 20:17:03 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: RE: TPs on THN

Question regarding the THN and masking. We recommend (b)(5)

(b)(5)

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 2:51 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Cc: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: TPs on THN

Apologies for the delay—cleaning it up still but ready for you to look
TPs on THN.docx

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Thu, 29 Dec 2022 14:13:22 +0000
To: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ); Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: TPs

Agree, t (b)(5)

(b)(5)

From: Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Sent: Thursday, December 29, 2022 9:04 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: RE: TPs

I actually don't think (b)(5)

(b)(5)

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Thursday, December 29, 2022 8:15 AM
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>; Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ) <mtq6@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: TPs

Have a question for you all. I find the bullet on (b)(5)

(b)(5)

(b)(5)

Lisa D. Rotz, MD, FIDSA
Acting Director
Division of Global Migration and Quarantine
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Email: LRotz@cdc.gov
Office: 404-639-4376
Mobile: 404-683-3832

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Thu, 29 Dec 2022 18:02:47 +0000
To: Stephen Morrison; Knight, Nancy W. EOP/NSC
Cc: Scott Kennedy
Subject: Re: U.S.-China Track 1.5 dialogue on health

Thanks Steve!

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Stephen Morrison <SMorriso@csis.org>
Sent: Thursday, December 29, 2022 12:53:48 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Knight, Nancy W. EOP/NSC
(b)(6)
Cc: Scott Kennedy <SKennedy@csis.org>
Subject: U.S.-China Track 1.5 dialogue on health

Dear Nancy and Henry

Below is the note that went to Rochelle and Sherri; Ashish Jha; Raj Panjabi and Hillary Carter; Derek Chollet (Counselor to Secy State) Mary Beth Goodman; Roger Glass; Atul Gawande; Erika Elvander; Loyce Pace and Michelle McConnell; Sheba Crocker in Geneva.

My colleague Scott Kennedy (copied) shared the concept with Rick Waters, Laura Rosenberger and Daniel Kritenbrink.

Thanks to you both for your generosity and guidance.

Best Steve

I wish to share with you a proposal for CSIS to organize a Track 1.5 dialogue on US-China health cooperation, which we hope will be launched early in the new year. (See attachment.)

This proposal is built on the foundation of CSIS's Commission on Strengthening America's Health Security and within it, a multi-year initiative focused on US-

China engagement on health issues. In late 2021, CFR's Yanzhong Huang and Scott Kennedy, the CSIS Trustee Chair on Chinese Business and Economics, published a report detailing potential avenues of collaboration. For the past 8 months we've been focused on exploring how to launch a Track 1.5 dialogue. This was a central area of focus during Scott's recent 7-week trip to China. He received positive signals from multiple quarters in China's public health community as well as the government, including from Vice Foreign Minister Xie Feng. At a one-on-one meeting on October 8, Xie Feng said he personally would assist in moving this idea through the Chinese bureaucracy.

We understand that coming out of the Biden-Xi meeting, dialogue on health is a potential high priority. We would welcome offering help to coordinate and manage this dialogue process. We are confident we could bring together the right parties from the US and China for a productive and results-oriented process.

Scott, Yanzhong and I would welcome a chance to speak with you soon about these ideas and how to build support for and implement them. The proposal has been shared at senior levels within the US government at the NSC (China), the Department of State (East Asia Pacific) and with the US ambassador and HHS health attaché in Beijing. On the China side, it has been shared with the Chinese ambassador to the United States, the Ministry of Foreign Affairs, and CASTED.

I am now circulating it to you and other senior officials involved in health, at the NSC, HHS, USAID, CDC, NIH and DOD. If the Track 1.5 dialogue moves forward, as we lay out, it will call upon the subject expertise that resides in these departments and agencies.

I look forward to hearing from you soon. And do hope you have a lovely and joyous holiday.

Warmest regards,

Steve

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 03:06:15 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: Re: Updated draft
Attachments: image00001.png

Thx

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Tuesday, December 27, 2022 9:57:34 PM
To: Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: Updated draft

Sherri, Henry—

Per our conversation, here is our current draft order with placeholders requesting additional language (see highlighted comments; kept the rest in there). I didn't pu (b)(5)
(b)(5)

Thanks,
Julia

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Sat, 31 Dec 2022 16:58:58 +0000
To: Kim, Lindsay (CDC/DDPHSIS/CGH/DGHP); Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ); Novak, Ryan (CDC/DDID/NCIRD/DBD)
Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD); Kim, Bryan (CDC/DDPHSIS/CGH/DGHP); Do, Trang T. (CDC/DDPHSIS/CGH/DGHP); Do, Thuy Thi Thu (CDC/DDPHSIS/CGH/DGHP); Nguyen, Nga T. (CDC/DDPHSIS/CGH/DGHT); Tomlinson, Hank (CDC/DDPHSIS/CGH/DGHT)
Subject: Re: URGENT: Govt of VN EOC meeting preparations regarding PRC travel order

To answer your second question, I also l (b)(5) (b)(5)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Kim, Lindsay (CDC/DDPHSIS/CGH/DGHP) <iyn2@cdc.gov>
Sent: Saturday, December 31, 2022 11:55:09 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Novak, Ryan (CDC/DDID/NCIRD/DBD) <bnk4@cdc.gov>
Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Kim, Bryan (CDC/DDPHSIS/CGH/DGHP) <bdk9@cdc.gov>; Do, Trang T. (CDC/DDPHSIS/CGH/DGHP) <win4@cdc.gov>; Do, Thuy Thi Thu (CDC/DDPHSIS/CGH/DGHP) <yhs0@cdc.gov>; Nguyen, Nga T. (CDC/DDPHSIS/CGH/DGHT) <qam7@cdc.gov>; Tomlinson, Hank (CDC/DDPHSIS/CGH/DGHT) <hjg7@cdc.gov>
Subject: Re: URGENT: Govt of VN EOC meeting preparations regarding PRC travel order

Hi Lisa -- Thanks for rapid response. @Do, Trang T. (CDC/DDPHSIS/CGH/DGHP), please review. Might be good t (b)(5)

Best,
Lindsay

Lindsay Kim, MD, MPH
Program Director, Division of Global Health Protection
U.S. Centers for Disease Control and Prevention (CDC) Vietnam
5th Floor, Tung Shing Square, 2 Ngo Quyen, Hanoi, Vietnam
Mobile/WhatsApp: +84 (0)90 6298466
Fax: +1-404-891-4934
Email: LKim@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Saturday, December 31, 2022 11:52 PM
To: Kim, Lindsay (CDC/DDPHSIS/CGH/DGHP) <iyn2@cdc.gov>; Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Novak, Ryan (CDC/DDID/NCIRD/DBD) <bnk4@cdc.gov>
Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Kim, Bryan (CDC/DDPHSIS/CGH/DGHP) <bdk9@cdc.gov>; Do, Trang T. (CDC/DDPHSIS/CGH/DGHP) <win4@cdc.gov>; Do, Thuy Thi Thu

(CDC/DDPHSIS/CGH/DGHP) <yhs0@cdc.gov>; Nguyen, Nga T. (CDC/DDPHSIS/CGH/DGHT) <qam7@cdc.gov>; Tomlinson, Hank (CDC/DDPHSIS/CGH/DGHT) <hjg7@cdc.gov>
Subject: Re: URGENT: Govt of VN EOC meeting preparations regarding PRC travel order

Hi Lindsay,
We don't have any slides for the order. Info and faq's on the links below may be helpful in answering questions.

Order: https://www.cdc.gov/quarantine/china-proof-negative-test.html

Attestation: https://www.cdc.gov/quarantine/pdf/attestation-proof-negative-covid-19-test-result-documentation-recovery-p.pdf

Operators FAQ: https://www.cdc.gov/quarantine/china-airline-faqs.html

Passengers FAQ: https://www.cdc.gov/coronavirus/2019-ncov/travelers/testing-international-air-travelers.html

Get Outlook for iOS
From: Kim, Lindsay (CDC/DDPHSIS/CGH/DGHP) <iyn2@cdc.gov>
Sent: Saturday, December 31, 2022 11:42:33 AM
To: Thaker, Kaytna (CDC/DDID/NCEZID/DGMQ) <xxb4@cdc.gov>; Novak, Ryan (CDC/DDID/NCIRD/DBD) <bnk4@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Kim, Bryan (CDC/DDPHSIS/CGH/DGHP) <bdk9@cdc.gov>; Do, Trang T. (CDC/DDPHSIS/CGH/DGHP) <win4@cdc.gov>; Do, Thuy Thi Thu (CDC/DDPHSIS/CGH/DGHP) <yhs0@cdc.gov>; Nguyen, Nga T. (CDC/DDPHSIS/CGH/DGHT) <qam7@cdc.gov>; Tomlinson, Hank (CDC/DDPHSIS/CGH/DGHT) <hjg7@cdc.gov>
Subject: URGENT: Govt of VN EOC meeting preparations regarding PRC travel order

Hello CDC HQ colleagues:

Happy early New Year from Vietnam. Thank you again for organizing the call on Thursday.

(b)(5)

Thanks,
Lindsay

Lindsay Kim, MD, MPH
Program Director, Division of Global Health Protection
U.S. Centers for Disease Control and Prevention (CDC) Vietnam
5th Floor, Tung Shing Square, 2 Ngo Quyen, Hanoi, Vietnam
Mobile/WhatsApp: +84 (0)90 6298466
Fax: +1-404-891-4934
Email: LKim@cdc.gov

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 22:55:50 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Lubar, Debra (CDC/DDID/NCEZID/OD); Jernigan, Daniel B. (CDC/DDPHSS/OD); Berger, Sherri (CDC/OD/OCS)
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: Re: Urgent: plan for attestation

(b)(5)

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 5:49:14 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: Urgent: plan for attestation

Hello,

As you know, all passengers departing on a flight (direct or connecting) from China to the US will be required to provide a negative test result and attest to the verification of the test, etc. Simple.

Now, we have added the test requirement for those passengers who have been in China over the last ten days and are flying to the US from Vancouver, Toronto, and Seoul. This afternoon, HHS confirmed that WH expects an attestation for those passengers who reply "yes" to being in China over the last ten days. (b)(5)

(b)(5)

This is a policy decision and wanted to make you all aware; please let me know if you have any questions. We would like to send it up by 7pm.

Thanks-
Julia

ATTACHMENT A-Proof of Negative Covid-19 Test Result or Documentation of Recovery for Air Passengers from the People's Republic Of China.docx

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Wed, 28 Dec 2022 23:08:25 +0000
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Charles, Julia (CDC/DDID/NCEZID/DGMQ); Lubar, Debra (CDC/DDID/NCEZID/OD); Jernigan, Daniel B. (CDC/DDPHSS/OD); Berger, Sherri (CDC/OD/OCS)
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ)
Subject: Re: Urgent: plan for attestation

Ok, I am fine with plan.

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 6:06:08 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: Re: Urgent: plan for attestation

I just sent you the #s

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Wednesday, December 28, 2022 6:04:03 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: Re: Urgent: plan for attestation

Ok

Sent via the Samsung Galaxy S22 5G, an AT&T 5G smartphone
Get Outlook for Android
From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Wednesday, December 28, 2022 6:02:59 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: Re: Urgent: plan for attestation

I support that approach. (b)(5)

(b)(5)

Lisa Rotz MD
Acting Director,
Division of Global Migration and Quarantine, CDC

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Wednesday, December 28, 2022 5:49:14 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Jernigan, Daniel B. (CDC/DDPHSS/OD) <dbj0@cdc.gov>; Berger, Sherri (CDC/OD/OCS) <sob8@cdc.gov>
Cc: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ) <gqw6@cdc.gov>
Subject: Urgent: plan for attestation

Hello,

As you know, all passengers departing on a flight (direct or connecting) from China to the US will be required to provide a negative test result and attest to the verification of the test, etc. Simple.

Now, we have added the test requirement for those passengers who have been in China over the last ten days and are flying to the US from Vancouver, Toronto, and Seoul. This afternoon, HHS confirmed that WH expects an attestation for those passengers who reply "yes" to being in China over the last ten days. (b)(5)

(b)(5)

This is a policy decision and wanted to make you all aware; please let me know if you have any questions. We would like to send it up by 7pm.

Thanks-
Julia

ATTACHMENT A-Proof of Negative Covid-19 Test Result or Documentation of Recovery for Air Passengers from the People's Republic Of China.docx

Julia Charles
(470) 217-9367
jcharles@cdc.gov

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Sun, 25 Dec 2022 18:57:36 +0000
To: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ); Rotz, Lisa (CDC/DDID/NCEZID/DGMQ); Lubar, Debra (CDC/DDID/NCEZID/OD)
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Walke, Henry (CDC/DDPHSIS/CPR/OD) replied to a comment in "Additions to PDT"

(b)(5)

From: Friedman, Cindy R. (CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>
Sent: Sunday, December 25, 2022 1:08 PM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>; Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: Walke, Henry (CDC/DDPHSIS/CPR/OD) replied to a comment in "Additions to PDT"

I just added sample size calcs but (b)(6)
(b)(6)
I think (b)(5)

(b)(5)

Cindy R. Friedman, MD
Chief, Travelers' Health Branch
Division of Global Migration and Quarantine
National Center for Emerging Zoonotic and Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA 30329

T: 404-639-1430\ C: 470-487-4373

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Sent: Sunday, December 25, 2022 12:48 PM
To: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Friedman, Cindy R.

(CDC/DDID/NCEZID/DGMQ) <ccf6@cdc.gov>; Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: FW: Walke, Henry (CDC/DDPHSIS/CPR/OD) replied to a comment in "Additions to PDT"

Hi Deb.

Sharing the next doc we're preparing based (b)(5) if you want to review as well. Several of us are (b)(6) (b)(6) think this is supposed to go up to HHS by 4pm, right Julia and Henry?

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <no-reply@sharepointonline.com>
Sent: Sunday, December 25, 2022 11:42 AM
To: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Subject: Walke, Henry (CDC/DDPHSIS/CPR/OD) replied to a comment in "Additions to PDT"

Additions to PDT.docx

CU **CDC User** left a comment

2 more replies

 **Friedman, Cindy R. (CDC/DDID/NCEZID** left a comment

 **Friedman, Cindy R. (CDC/DDID/NCEZID** left a comment

 **Walke, Henry (CDC/DDPHSIS/CPR/OD)** replied

Go to comment

Why am I receiving this notification from Office?

Microsoft

Privacy Statement | Notification Settings

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Thu, 29 Dec 2022 17:51:29 +0000
To: Haynes, Benjamin (CDC/OD/OADC)
Cc: Nordlund, Kristen (CDC/OD/OADC)
Subject: RE: Wastewater testing of airplanes from China

No problem

From: Haynes, Benjamin (CDC/OD/OADC) <fxq2@cdc.gov>
Sent: Thursday, December 29, 2022 12:51 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Nordlund, Kristen (CDC/OD/OADC) <hok4@cdc.gov>
Subject: Re: Wastewater testing of airplanes from China

Thank you. We will quit bugging you ☺

Benjamin N. Haynes
404-451-4039

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Thursday, December 29, 2022 12:50 PM
To: Haynes, Benjamin (CDC/OD/OADC) <fxq2@cdc.gov>
Cc: Nordlund, Kristen (CDC/OD/OADC) <hok4@cdc.gov>
Subject: RE: Wastewater testing of airplanes from China

(b)(5)

(b)(5)

From: Haynes, Benjamin (CDC/OD/OADC) <fxq2@cdc.gov>
Sent: Thursday, December 29, 2022 12:13 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Cc: Nordlund, Kristen (CDC/OD/OADC) <hok4@cdc.gov>
Subject: Fw: Wastewater testing of airplanes from China

Henry,
I saw this circulating on Twitter, (b)(5) Thoughts?

Benjamin N. Haynes
404-451-4039

From: Steenhuysen, Julie D. (Reuters) <julie.steenhuysen@thomsonreuters.com>
Sent: Thursday, December 29, 2022 12:09 PM
To: Haynes, Benjamin (CDC/OD/OADC) <fxq2@cdc.gov>
Cc: Nordlund, Kristen (CDC/OD/OADC) <hok4@cdc.gov>
Subject: Wastewater testing of airplanes from China

Hi Benjamin and Kristen,

I heard today from a source that the US government is considering testing wastewater from airplanes coming from China as a better way to identify new variants. Can you confirm?

Thanks,

Julie

Julie Steenhuysen
US Health & Science Correspondent
311 S Wacker Dr. STE 1200
Chicago, Il. 60606

Thomson Reuters
Mobile 312-371-4017
Julie.Steenhuysen@thomsonreuters.com
@JDSteenhuysen

You can view my latest stories here:
https://www.reuters.com/journalists/julie-steenhuysen

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Thu, 29 Dec 2022 12:57:44 +0000
To: Yee, Sue Lin (CDC/DDPHSIS/CGH/DGHP); Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Cc: Schluter, W. William (CDC/DDPHSIS/CGH/OD); Novak, Ryan (CDC/DDID/NCIRD/DBD)
Subject: RE: [EXTERNAL] RE: Text of Health Alert for COVID-19 Pre-Departure Testing Requirement and CDC Talking Points

Awesome! Thanks Sue Lin.

From: Yee, Sue Lin (CDC/DDPHSIS/CGH/DGHP) <sby9@cdc.gov>
Sent: Thursday, December 29, 2022 7:57 AM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>; Rotz, Lisa (CDC/DDID/NCEZID/DGMQ) <ler8@cdc.gov>
Cc: Schluter, W. William (CDC/DDPHSIS/CGH/OD) <wbs8@cdc.gov>; Novak, Ryan (CDC/DDID/NCIRD/DBD) <bnk4@cdc.gov>
Subject: Fwd: [EXTERNAL] RE: Text of Health Alert for COVID-19 Pre-Departure Testing Requirement and CDC Talking Points

Hi, Julia and Lisa:

Not sure if HQ plans to post a Chinese version of the health alert, but here are the translated versions (short and long) that are on Embassy Beijing's page in case they are useful. Thanks!

Sue Lin

From: Sevy, Travis M (Beijing) <SevyTM@state.gov>
Sent: Thursday, December 29, 2022 5:10 PM
To: Yee, Sue Lin (CDC/DDPHSIS/CGH/DGHP) <sby9@cdc.gov>; Elvander, Erika D (Beijing) <ElvanderED@state.gov>; Chapman, Jonathan (FDA/OC) <Jonathan.Chapman@fda.hhs.gov>; Okwuje, Ifeoma M.F. (Beijing) <OkwujeIMF@state.gov>; Harrington, Maxwell S (Beijing) <HarringtonMS@state.gov>; Bistransky, William J (Beijing) <BistranskyWJ@state.gov>
Cc: Shaw-Dore, Vanessa (FDA/OC) <Vanessa.Shaw-Dore@fda.hhs.gov>; Meale, David (Beijing) <MealeD@state.gov>; Turner, Marybeth K (Beijing) <TurnerMK@state.gov>; Beijing EXEC Staffers <BeijingEXEC@state.gov>; Champlin, Meredith L (Beijing) <ChamplinML@state.gov>; Yee, SueLin (Beijing) <YeeSL@state.gov>; Guthrie, Phillip M (Beijing) <GuthriePM@state.gov>; Yang, Forest (Beijing) <yangjf@state.gov>; China Consular Chiefs <ChinaConsularChiefs2@state.gov>; China ACS Chiefs <ChinaACSChiefs@state.gov>; Beijing Press Office <BeijingPressOffice@state.gov>
Subject: RE: [EXTERNAL] RE: Text of Health Alert for COVID-19 Pre-Departure Testing Requirement and CDC Talking Points

Bilingual versions of the full Health Alert (directed at U.S. citizens) has gone out as a MASCOT message to all U.S. citizens in China registered in STEP. It's also been posted to the embassy website.

The shorter version from travel.state.gov (directed to non U.S. citizens) has been posted to our external visa appointment scheduling website.

Cleared Chinese language versions of both notices are attached.

Huge thanks to PAS for reviewing our translations and posting on the various sites!

Travis

From: Walke, Henry (CDC/DDPHSIS/CPR/OD)
Sent: Mon, 26 Dec 2022 21:29:11 +0000
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: RE: ?

See my chat

From: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Sent: Monday, December 26, 2022 4:24 PM
To: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Subject: RE: ?

(b)(5)

From: Walke, Henry (CDC/DDPHSIS/CPR/OD) <hfw3@cdc.gov>
Sent: Monday, December 26, 2022 4:21 PM
To: Charles, Julia (CDC/DDID/NCEZID/DGMQ) <yyb1@cdc.gov>
Subject: ?

(b)(5)

Henry Walke, MD, MPH (he/him)
Director, Center for Preparedness and Response (CPR)
CDC, HHS
+1-404-639-3582 (office)
+1-404-452-9624 (mobile)
hwalke@cdc.gov

From: Rotz, Lisa (CDC/DDID/NCEZID/DGMQ)
Sent: Thu, 29 Dec 2022 13:14:51 +0000
To: Shockey, Caitlin E. (CDC/DDID/NCEZID/DGMQ); Sood, Neha Jaggi (CDC/DDID/NCEZID/DGMQ)
Cc: Charles, Julia (CDC/DDID/NCEZID/DGMQ)
Subject: TPs
Attachments: 2022 12 28 China Covid TPs.docx

Have a question for you all. I find the bullet (b)(5)

(b)(5)

(b)(5)

Lisa D. Rotz, MD, FIDSA
Acting Director
Division of Global Migration and Quarantine
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Email: LRotz@cdc.gov
Office: 404-639-4376
Mobile: 404-683-3832

(b)(5)

(b)(5)

(b)(5)